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Stroke is the second most common cause of death (after ischemic heart disease) 
and a major cause of disability worldwide [1]. It is defined as the rapidly developing 
loss of brain functions due to occlusion or rupture of the cerebral blood vessels. 
Hippocrates (460 to 370 BC) was first to describe the phenomenon “stroke” by 
sudden paralysis. Later, in 1658, Johann Jacob Wepfer (1620–1695) identified 
two types of stroke, ischemic or haemorrhagic. He also described the rapid 
recovery of neurological symptoms, which would nowadays be referred to as 
transient ischemic attacks (TIA’s). 
The traditional definition of stroke, devised by the World Health Organisation in 
the 1970s [2], is a "neurological deficit of cerebrovascular cause that persists 
beyond 24 hours or is interrupted by death within 24 hours". Stroke due to ischemia 
(80% of all reported stroke incidents) is caused by an occlusion of a blood vessel 
in the neck or brain due to a thrombosis or embolism. The 24-hour limit arbitrarily 
distinguishes ischemic stroke from transient ischemic attack (TIA), which is a 
related syndrome of stroke symptoms that resolve completely within 24 hours. 
A haemorrhagic stroke (20%) is caused by rupture of a blood vessel resulting in 
either an intracerebral haemorrhage (15%) or a subarachnoid haemorrhage (5%). 
The clinical symptoms often depend on the location of the stroke. These symptoms 
include “visible” consequences such as hemiparesis, aphasia, dysarthria or 
visual deficits. In the first few days to weeks after stroke, common clinical practice 
mainly focuses on rehabilitation of these “visible” consequences of stroke. 
Improvement of these motor or language limitations is usually seen in the first 
days to weeks after the acute stroke event. Then, after these periods with often 
strenuous rehabilitation medicine, the “non visible” or behavioural consequences 
after stroke such as depressive symptoms, cognitive decline or fatigue become 
apparent. 
Many studies investigated the prevalence and risk factors of these behavioural 
consequences of stroke. However, these studies differed tremendously in terms 
of patient inclusion (age, gender, number of patients that were used) and times 
following the stroke at which the behavioural assessments were performed. That 
makes comparison between studies difficult. Furthermore, most studies did not 
take into account that some so-called post-stroke behavioural consequences 
may already present before the stroke. Therefore, complete information should be 
present on the presence of pre-stroke characteristics (for example depression 
and cognitive decline  in the medical history or white matter lesions, previous 
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stroke and cerebral atrophy) that themselves, independent from the stroke, may 
be related to depressive symptoms [3-5], impaired cognition [6-10], fatigue [11-13] 
and consequently could confound the stroke – behaviour relation. Most studies 
on the epidemiology of post-stroke behavioural consequences are cross sectional 
in nature and prospective studies are still scare. In addition they usually do not 
attempt to investigate underlying mechanisms of these behavioural consequences. 
For example, post-stroke cognitive dysfunction is usually well explained by the 
size and location of the infarction. An explanation of the occurrence of memory 
dysfunction after stroke (especially episodic memory dysfunction) is currently 
lacking, as there is almost never an infarction in the medial temporal lobe (MTL). 
A proper MTL function is essential for memory encoding and retrieval. With the 
aid of fMRI we tried to find an explanation for this frequently observed post-stroke 
memory dysfunction. 
The aim of this thesis is to report on frequency, time-course and risk factors of 
several post-stroke behavioural consequences including depressive symptoms, 
cognitive dysfunction and fatigue. We wanted to do so by taking the effect of 
possible confounders from the medical history, pre-stroke neuroimaging and 
stroke characteristics into account. 
The studies presented in this thesis are based on the ongoing Nijmegen Stroke 
Study. This database has started in 2005 and prospectively investigates short- 
and long-term consequences of stroke with regular pre-planned assessments 
after stroke. 
The first part of this thesis (chapter 2) is devoted to post-stroke depressive 
symptoms (PSDS) in stroke survivors. It starts with a systematic review that 
investigates available data on frequency, time-course, possible confounders from 
the medical history, pre-stroke neuroimaging characteristics and risk factors of 
PSDS (chapter 2.1). Secondly, chapter 2.2 cross-sectionally investigates the risk 
factors of post-stroke depressive symptoms among 420 patients with different 
stroke subtypes by taking possible pre- and stroke related confounders into 
account.
The second part of this thesis (chapter 3.1) systematically reviews on frequency, 
time-course and risk factors of post-stroke memory function. In chapter 3.2, we 
attempted to investigate the etiology of a reduced post-stroke memory 
performance with the aid of fMRI. 
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In chapter 4 we prospectively investigate the frequency and risk factors of 
post-stroke fatigue among 108 patients with a cerebral infarction. 
In the final part of this thesis (chapter 5) the main findings are summarised and 
discussed. All new findings are put in perspective and suggestions for clinical 
practice and future research are put forward. 
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2.1 Epidemiology of post-stroke depressive symptoms 
Abstract
Many studies described the frequency and risk factors of post-stroke depression/
depressive symptoms, although they often lack assessment of confounders (such as 
depression in the medical history, white matter lesions, atrophy) that may be related 
to depression, independent from the stroke. We therefore systematically reviewed 
available data on post-stroke depression by taking the previously mentioned 
confounding factors into account. 
We performed a systematic PubMed and Embase search with the following medical 
subject heading terms and text words: cerebrovascular disorder, brain infarction and 
depression. The search yielded 1796 papers; 107 fulfilled inclusion criteria. 
Patients with post-stroke physical/cognitive impairment or depression in their medical 
history had the highest prevalence of post-stroke depression/depressive symptoms. 
There were almost no studies that adjusted for confounders in multivariate analysis. 
This study reviews the largest number of papers in this area thus far. This review found 
that psychiatric or depressive disorders in the medical history or post-stroke physical 
limitations are related with post-stroke depression/depressive symptoms rather than 
stroke specific (location, size) factors. Virtually no study reported on adjustment for 
confounding factors. 
Liselore Snaphaan  and Frank-Erik de Leeuw. Post-stroke depression:  
a systematic review on pre- and post-stroke clinical and neuroimaging correlates. 
Aging Health. June 2009, 5:449-449
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Introduction
Depression and depressive symptoms after stroke (PSD/PSDS) frequently occur and 
they interfere with successful stroke recovery [1-3]. Some suggest a causal role for 
the stroke itself or related factors, whereas others view its occurrence as a reaction on 
a major life event. PSD and PSDS incidence varies dramatically across studies from 
16% to 74% and 11% to 78%, respectively. The interpretation and reproducibility of 
these figures is limited, in part due to methodological differences between studies. 
A standardised assessment of depression after stroke may aid in establishing a true 
estimate of its prevalence and a better understanding of its etiology. 
To investigate whether indeed the stroke itself is responsible for the emergence of 
depression after a stroke this should preferably be assessed in first-ever stroke 
patients after a standardised stroke – depression assessment time interval. In addition, 
complete information should be available on the presence of psychiatric or depressive 
disorders in the medical history, stroke characteristics (including size, location, clinical 
severity and degree of disability) and pre-stroke neuroimaging characteristics (such 
as white matter lesions, silent brain ischemia, medial temporal lobe atrophy, cortical 
atrophy) that themselves may be related to depressive symptoms, independent from 
the stroke and consequently could confound the stroke – depression relation. 
From an etiological point of view one should study first-ever stroke patients that should 
be as free as possible from the earlier mentioned characteristics. From a clinical 
(prognostic) point of view one would preferably investigate all stroke patients with 
complete information on all the previously mentioned items in order to identify 
prognostic factors for PSD/PSDS. One of the reasons for the controversy around the 
post-stroke depression concept is because of its poor operationalisation. Secondly, 
because of a lack of standardised assessment of potential confounders, even in some 
previous reviews on PSD and PSDS [4-6]. Another explanation for the ongoing 
controversy is that many separate reports deal with data from one single cohort. 
The aim of the present study was therefore to systematically review the available data 
on frequency, time-course and risk factors of PSD/PSDS in stroke survivors. Secondly, 
we aimed to evaluate the effect of the previously mentioned possible confounders 
from the medical history, pre-stroke neuroimaging characteristics and stroke 
characteristics on the prevalence of PSD/PSDS, by carefully avoiding double counting 
of multiple reports derived from single cohorts. 
2
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Methods
A literature search of PubMed and Embase computerised databases was performed 
in 2008. We included all papers dealing with stroke and depression and therefore 
entered the following medical subject heading (MeSH) terms and text words in full 
and truncated: ‘cerebrovascular disorder, brain infarction and depression. In 
accordance with the literature the term cerebrovascular disorder included both 
cerebral infarcts and intracerebral haemorrhages. The search was limited to the 
English language, to those papers with abstracts, and included human studies with 
participants of 45 years of age or over. 
We followed a two-step approach in the selection of eligible articles (see figure 1). 
First, one reviewer (LS) screened the abstracts for the following characteristics: (1) 
original paper, published in English on case-control or cohort studies (sample size 
had to be at least 20), and (2) information about depression and stroke. From screen 
positive abstracts full papers were collected and went into a second selection step to 
chapter 2
1796 abstracts were retrieved from PUBMED and EMBASE search on 
cerebrovascular disorder, brain infarction and depression   
391 articles  
fulfilled inclusion  
criteria 1 and 2 
107 articles fulfilled 
inclusion criteria 3-8 
Step 2 Step 2 
Step 1 Step 1 
1327 articles excluded  
on the basis of only the 
abstract
 
78 articles excluded  
on the basis of duplicates 
between databases  
Step 1 
284 articles were 
excluded  
Figure 1  The stepwise approach in the selection of eligible and  
included articles
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identify papers that fulfilled the following inclusion criteria: (3) description of the stroke 
(clinically well defined sudden onset of a neurological deficit with a corresponding 
lesion on neuroimaging); in addition information on at least one of the following five 
characteristics had to be present: (4) stroke location and severity, (5) description and 
operationalisation of depression/depressive symptoms according to international 
diagnostic criteria (6) at least 50% first-ever stroke survivors in the study population 
(7) information on neuroimaging characteristics (at least one of the following: white 
matter lesions, silent brain infarction and medial temporal lobe atrophy) and (8) 
information on pre-stroke (bio)psychological factors (medical history of depression/
depressive episodes and/or psychiatric disease). Papers were evaluated in this 
second selection criteria by two authors independently (LS and FEdL). In case of 
disagreement a consensus meeting was held. 
The Pubmed and Embase search strategy yielded 1796 papers. After screening of the title 
and the abstracts, 391 papers were retrieved full-text and examined against the inclusion 
criteria, of which 107 were included and went on to the data extraction stage (figure 1). 
Results
In total 45 studies investigated the presence of PSD at one or more time-points after 
stroke and 62 studies investigated PSDS at one or more time-points after stroke. PSD 
was diagnosed on basis of the criteria of Diagnostic and Statistical Manual of Mental 
Disorders (DSM) version III [7] (n=30 studies), DSM version IV [8] (n=12 studies) or 
Research Diagnostic Criteria [9] (RDC: n=3 studies). PSDS was defined by the 
following rating scales; Hamilton Depression Rating Scale (HDRS) [10], (n= 14 
studies), Beck Depression Inventory (BDI) [11], (n=12 studies), Hospital anxiety and 
depression scale (HADS) [12], (n=10 studies), Centre for epidemiologic studies 
depression scale (CES-D)[13], (n=10 studies), Zung Self-Rating Depression Scale 
(ZDS) [14], (n=6 studies), Montgomery-Asberg Depression Rating Scale (MADRS) 
[15], (n=6 studies), Geriatric Depression Scale (GDS) [16], (n=2 studies), Cornell 
Depression Scale (CDS) [17], (n=1 study), Clinical Interview Schedule-Revised (CIS-R) 
[18], (n=1 study). 
Prevalence and time-course of PSD/PSDS
The prevalence of PSD/PSDS measured at more than one time-point within studies 
(n=25, table 1) varied from 5% to 79% within one month after stroke, which showed a 
tendency to decline to 8% to 59% one year after stroke, although six studies 
2
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[19,20,21,22,23,24] showed a stable time-course (stroke survivors investigated 
n=976, range n=25-436) while six studies [25,26,27,28,29,30] showed an increase of 
PSD/PSDS after longer stroke – depression assessment intervals (stroke survivors 
investigated n=840, range n=80-189). The prevalence of PSD/PSDS that was 
assessed at one single time-point per study (n=83) varied between 16-74% and 
11-78%, respectively (data not shown).
Post-stroke characteristics and PSD/PSDS
Type of stroke (infarction versus haemorrhage), size, side, localisation, stroke 
severity and aphasia
Most studies (table 2, 3) did not find any relation between type (infarction versus 
haemorrhage) and size of stroke, nor with aphasia (the Western Aphasia Battery [31] 
was most commonly used) and the presence of PSD/PSDS. Thirty-three studies 
(stroke survivors n=5964, range n=26-662) did not find a relationship between lesion 
side and PSD/PSDS, although seven studies [32-38] (stroke survivors n=506, range 
n=25-141) found an increased prevalence of PSD/PSDS among those with a left sided 
lesion, whereas one study [39] (n=145) found this among those with a right sided 
lesion. Some studies investigated the effect of localisation on PSD and PSDS in more 
anatomical detail. Most studies [26,40,41,42,43,44,45,46,47,48,49,28,35,50,36,37,51,5
2,53] (stroke survivors investigated n=2590, range n=20-421) found a relation 
between PSD/PSDS and infarcts in the anterior part of the brain, especially in the left 
anterior hemisphere. One study [54](n=120) found an increased prevalence of PSD 
among patients with infarcts in the posterior part of the brain (hemisphere not 
specified). Four studies [55,56,20,29] (stroke survivors investigated n=475, range 
n=89-161) found a higher prevalence of PSD/PSDS among those with a more severe 
stroke, whereas three studies [38,57,58] (stroke survivors investigated n= 201, range 
n=33-95) did not (table 2, 3). 
Pre-stroke neuroimaging characteristics and PSD/PSDS 
There are a number of factors that presumably were already present before stroke 
(such as a (silent) previous infarction, white matter lesions (WML), medial temporal 
lobe atrophy (MTA) and cerebral atrophy) that have found to be related with depressive 
symptoms or depression irrespective of a stroke [59-61]. Consequently, their presence 
could explain depressive symptoms or depression in stroke patients, not necessarily 
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related to the stroke. As a result of the fact that stroke survivors usually did not have 
neuroimaging before the actual stroke, the effects of these factors on PSD/PSDS are 
difficult to disentangle from the direct stroke effects. Nine [30,52,60-67] studies tried 
to overcome this problem by rating these characteristics on neuroimaging performed 
during the stroke diagnosis (table 4). One study [60] (stroke survivors included n=80) 
found an increased prevalence of PSD among those with the most severe cortical 
atrophy than those without, whereas others (stroke survivors investigated n=1506, 
range n=70-395) did not find any relation between any of the mentioned pre-stroke 
neuroimaging characteristics and PSD/PSDS.  
Demographics, pre-stroke (bio)psychological and post-stroke clinical 
characteristics and PSD/PSDS
Age, sex, education level and marital status
Most studies didn’t find any relation between age, sex, education or marital state and 
PSD/PSDS (table 5, 6). 
Pre-stroke psychiatric or depressive disorders in the medical history
Eleven of the 20 studies [59,68,43,69,21,70,71,33,53,52,66] (stroke survivors 
investigated n=2684, range n=52-739) indicated a higher occurrence of PSD/PSDS 
among those with a history of depression (table 5, 6). In the remaining studies 
[30,72,42,44,32,73,74,54,51] (stroke survivors investigated n=1322, range n=50-421) 
there was no such relation.
Post-stroke physical disability
In 27 studies (stroke survivors investigated n=5201, range n=35-739) a higher 
prevalence of PSD/PSDS was found among those with a higher degree of physical 
disability than those without (table 5, 6). In seven studies [30,59,32,2,33,50,75] (stroke 
survivors investigated n=981, range n=38-285) no such relation was found. 
Post-stroke cognitive function
Thirteen studies [59,41,42,2,49,62,63,50,75,74,76,29,23] (stroke survivors investigated 
n=2030, range n=38-421) found a higher prevalence of PSD/PSDS among those with 
2
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Table 1 Prevalence of post-stroke depression and depressive symptoms: a time-course
Depression
Ref
n
mean age/
range 
(yrs(SD))
proportion
first-ever
stroke (%)
screenings tool 
depression
 
prevalence of post-stroke depression (%)
by stroke – depression assessment interval (months)
change
over
time
<1 1 2-4 5-6 7-9 12 >12
[72] 50 51(1) 100 DSM IV 20 4 ↓
[26] 80 73(ng) 80 DSM III-R 25 31 29(3yr)* ↑
[80] 70 73(ng) 80 DSM III-R 29 30 24 ↓
[82] † 106 66(12) 100 DSM III-R 48 37 ↓
[83] † 106 66(ng) 100 DSM III-R 46 36 ↓
[81] 128 71(ng) 100 DSM III 43 32 22 ↓
[28] 103 59(13) 76 DSM III 35 47 60 ↑
[32] 99 71(10) 76 DSM III 35 13 ↓
[22] 50 60(12) 84 DSM IV 44 40 44 =
[30] 189 69(12) 100 DSM IV 22 39 ↑
Depressive 
symptoms 
Ref
screenings 
tool depressive 
symptoms
cut-off
prevalence of post-stroke depressive symptoms (%)
by stroke – depression assessment interval (months)
change
over
time
[66] 202 75(ng) 88 MADRS ≥7 43 36 18(3yr)* ↓
[21] 436 75(12) 83 MADRS ≥7 27 22 ↓
ZDS ≥50 22 21 =
[85] 162 67(ng) 100 CES-D ≥23 34 25 ↓
[59] 285 69(ng) 74 HDRS ≥13 79 30 ↓
[20] 161 67(13) 100 BDI >10 41 42 =
[47] 128 71(14) 100 BDI ≥13 20 8 ↓
[27] 153 35-75 100 HDRS >17 29 32 60 ↑
[25] 190 69(12) 100 BDI/HADS 9/10 and 7/8 22 26 30 34 39 ↑
[56] 100 55(11) 100 BDI ≥10 27 29 23 24 26 ↓
[29] 125 76(ng) 70 HADS >8 5 16 21 ↑
[44] 26 63(9) 100 HDRS ≥13 31 34 =
[57] 95 67(11) 100 CESD ≥16 69 48 ↓
[23] 104 59(10) 100 CDS ≥11 24 25 =
[24] 145 73(12) 100 MADRS ≥12 55 59 =
[86] 200 72(11) 58 GSD ≥5 60 35 ↓
Empty cells: no assessment, ng: not given, DSM: Diagnostic and Statistical Manual of Mental Disorders, 
MADRS: Montgomery-Asberg Depression Rating scale, ZDS: Zung Self Rating Depression Scale,  
CES-D: Centre for epidemiological Studies Depression scale, HDRS: Hamilton Depression Rating Scale, 
BDI: Becks Depression Inventory, HADS: Hospital Anxiety Depression Scale, CDS: Cornell Depression 
Scale, ↓ Indicates at least a 10% decrease in the prevalence of post-stroke depression/depressive 
25
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Table 1 Prevalence of post-stroke depression and depressive symptoms: a time-course
Depression
Ref
n
mean age/
range 
(yrs(SD))
proportion
first-ever
stroke (%)
screenings tool 
depression
 
prevalence of post-stroke depression (%)
by stroke – depression assessment interval (months)
change
over
time
<1 1 2-4 5-6 7-9 12 >12
[72] 50 51(1) 100 DSM IV 20 4 ↓
[26] 80 73(ng) 80 DSM III-R 25 31 29(3yr)* ↑
[80] 70 73(ng) 80 DSM III-R 29 30 24 ↓
[82] † 106 66(12) 100 DSM III-R 48 37 ↓
[83] † 106 66(ng) 100 DSM III-R 46 36 ↓
[81] 128 71(ng) 100 DSM III 43 32 22 ↓
[28] 103 59(13) 76 DSM III 35 47 60 ↑
[32] 99 71(10) 76 DSM III 35 13 ↓
[22] 50 60(12) 84 DSM IV 44 40 44 =
[30] 189 69(12) 100 DSM IV 22 39 ↑
Depressive 
symptoms 
Ref
screenings 
tool depressive 
symptoms
cut-off
prevalence of post-stroke depressive symptoms (%)
by stroke – depression assessment interval (months)
change
over
time
[66] 202 75(ng) 88 MADRS ≥7 43 36 18(3yr)* ↓
[21] 436 75(12) 83 MADRS ≥7 27 22 ↓
ZDS ≥50 22 21 =
[85] 162 67(ng) 100 CES-D ≥23 34 25 ↓
[59] 285 69(ng) 74 HDRS ≥13 79 30 ↓
[20] 161 67(13) 100 BDI >10 41 42 =
[47] 128 71(14) 100 BDI ≥13 20 8 ↓
[27] 153 35-75 100 HDRS >17 29 32 60 ↑
[25] 190 69(12) 100 BDI/HADS 9/10 and 7/8 22 26 30 34 39 ↑
[56] 100 55(11) 100 BDI ≥10 27 29 23 24 26 ↓
[29] 125 76(ng) 70 HADS >8 5 16 21 ↑
[44] 26 63(9) 100 HDRS ≥13 31 34 =
[57] 95 67(11) 100 CESD ≥16 69 48 ↓
[23] 104 59(10) 100 CDS ≥11 24 25 =
[24] 145 73(12) 100 MADRS ≥12 55 59 =
[86] 200 72(11) 58 GSD ≥5 60 35 ↓
symptoms between first and last assessment , = Stable prevalence of PSD over time (plus or minus 10% 
between first and last assessment), ↑ Indicates at least a 10% increase in the prevalence of post-stroke 
depression/depressive symptoms between first and last assessment, 
* indicates the stroke-depression/depressive symptoms assessment Interval, † multiple publication 
based on virtually the same patient cohort.
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Table 2 Relation between the occurrence of post-stroke depression and stroke characteristics 
Ref n
mean age/
range 
(yrs(SD))
proportion
first-ever 
stroke (%)
stroke - depression 
assessment interval
(months)
type of stroke (%)
side (%) posterior/anterior
part of the brain
size 
(volume)
stroke severity* aphasia
<1 1-6 7-12 >12 infarction relation left relation left/right relation assessed relation assessed relation assessed relation
[51] 159 67(ng) 75 + 100 L/R Anterior ↑ †
[40] 273 64(16) 100 + + 100 45 N L Anterior ↑ † Y N Y ↑
[64] 70 70(ng) 100 + 100 L/R Y N
[72] 50 51(1) 100 + + 54 Y N Y
[98] 126 ng 100 + I/H 46 N
[99] 301 55(ng) 56 + 80 57 N Y N
[26] 80 44-100 80 + + + + 79 50 L Anterior ↑ Y N
[37] 25 late 50-60 100 + I/H 56 L↑ L Anterior ↑ Y N
[100] 53 59(ng) 100 + I/H N 49 N Y N
[101] 30 57(ng) 73 + I/H 60 L↑ L/R Anterior↑
[81] 128 18-96 100 + + 30 Y N
[73] 94 70(ng) 52 + + I/H N ng N
[74] 60 >75=45% 100 + 81 52 Y ↑
[44] 130 68(ng) 100 + 45 N L/R Both↑
[43] 87 63(14) 68 + 36 N L Anterior ↑ Y ↑
[50] 38 55(ng) 100 + I/H 76 L/R Anterior ↑ Y ↓
[54] 120 58(ng) 100 + I/H 23 L/R Posterior↑ Y N
[33] 141 56(ng) 83 + 79 N 45 L↑ Y N
[32] 99 71(10) 76 + 82 47 L↑
[49] 41 70(ng) 100 + I/H 59 L Anterior ↑ Y
[77] 190 69(12) 100 + 100 47 N L/R N
[52] 275 71(7) 70 + I/H L Anterior ↑ Y N
[102] 149 81(5) 73 + 94 ng N
[30] 189 69(12) 100 + + 100 47 N L/R N Y N
Empty cells: no assessment, ng: not given, Y: Yes, N: No, + indicates timing of post-stroke depression 
assessment, I: Infarction, H: Haemorrhage, I/H: Infarction/Haemorrhage proportion not given, L: Left 
hemisphere, R: Right hemisphere, L/R: Left/Right lesion proportion not given, * assessed by NIHSS: 
(National Institute of Health Stroke Scale) or SSS (Scandinavian Stroke Scale), A: Anterior part of the 
brain, P: Posterior part of the brain, † anterior cerebral artery, ↑ higher prevalence of post-stroke 
depression among stroke patients with a left sided stroke/anterior or posterior lesion/larger lesion 
volume/aphasia, ↓ lower prevalence of post-stroke depression among stroke patients with a smaller 
lesion volume. 
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Table 2 Relation between the occurrence of post-stroke depression and stroke characteristics 
Ref n
mean age/
range 
(yrs(SD))
proportion
first-ever 
stroke (%)
stroke - depression 
assessment interval
(months)
type of stroke (%)
side (%) posterior/anterior
part of the brain
size 
(volume)
stroke severity* aphasia
<1 1-6 7-12 >12 infarction relation left relation left/right relation assessed relation assessed relation assessed relation
[51] 159 67(ng) 75 + 100 L/R Anterior ↑ †
[40] 273 64(16) 100 + + 100 45 N L Anterior ↑ † Y N Y ↑
[64] 70 70(ng) 100 + 100 L/R Y N
[72] 50 51(1) 100 + + 54 Y N Y
[98] 126 ng 100 + I/H 46 N
[99] 301 55(ng) 56 + 80 57 N Y N
[26] 80 44-100 80 + + + + 79 50 L Anterior ↑ Y N
[37] 25 late 50-60 100 + I/H 56 L↑ L Anterior ↑ Y N
[100] 53 59(ng) 100 + I/H N 49 N Y N
[101] 30 57(ng) 73 + I/H 60 L↑ L/R Anterior↑
[81] 128 18-96 100 + + 30 Y N
[73] 94 70(ng) 52 + + I/H N ng N
[74] 60 >75=45% 100 + 81 52 Y ↑
[44] 130 68(ng) 100 + 45 N L/R Both↑
[43] 87 63(14) 68 + 36 N L Anterior ↑ Y ↑
[50] 38 55(ng) 100 + I/H 76 L/R Anterior ↑ Y ↓
[54] 120 58(ng) 100 + I/H 23 L/R Posterior↑ Y N
[33] 141 56(ng) 83 + 79 N 45 L↑ Y N
[32] 99 71(10) 76 + 82 47 L↑
[49] 41 70(ng) 100 + I/H 59 L Anterior ↑ Y
[77] 190 69(12) 100 + 100 47 N L/R N
[52] 275 71(7) 70 + I/H L Anterior ↑ Y N
[102] 149 81(5) 73 + 94 ng N
[30] 189 69(12) 100 + + 100 47 N L/R N Y N
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Table 3  Relation between the occurrence of post-stroke depressive symptoms  
and stroke characteristics
Ref n 
mean age/
range
(yrs(SD))
proportion
first-ever
stroke
(%) 
stroke – depressive 
symptoms 
assessment interval 
(months)
type of stroke (%) side (%)
posterior/anterior
part of the brain
size
(volume)
stroke severity* aphasia
<1 1-6 7-12 >12 infarction relation left relation left/right relation assessed relation assessed relation assessed relation
[62] 126 62(13) 100 + 88 42 N Y ↑
[58] 35 55-91 72 + 87 N Y N
[66] 202 75(ng) 88 + + 88 46 L/R
[103] 72 33-85 100 + I/H 51 N Y
[39] 145 18-93 75 + I/H 55 R↑ L/R Y ↑
[21] 436 75(12) 83 + + 86 49 N Y
[46] 47 24-79 100 + 88 68 L Anterior ↑ † Y N
[48] 20 53(9) 100 + I/H 45 L/R Anterior↑ Y N
[104] 148 62(ng) 100 + 85 N 54 N L/R N Y N
[41] 417 68(ng) 81 + I/H ng N L/R Anterior ↑ †
[59] 285 25-80 74 + 81 ng N Y N
[20] 161 67(13) 100 + + 85 ng N Y ↑
[47] 128 71(14) 100 + + 81 34 N L/R Anterior ↑
[36] 35 66(ng) 100 + I/H 54 L↑ R Both↑ Y ↑
[28] 48 59(ng) 100 + 46 L Anterior ↑ Y Y N
[55] 89 55(11) 100 + 100 42 Y ↑ Y N
[105] 60 71(11) 100 + I/H 52 N Y ↑
[34] 103 63(11) 74 + + + I/H 46 L↑ Y N
[27] 153 35-75 100 + + N
[106] 662 63(ng) 71 + I/H N 48 N Y N
[107] 50 51-89 100 + 22 N
[42] 421 72(8) 75 + I/H 34 L/R Both↑ † Y
[73] 192 62(13) 100 + 83 40 N Y N
[56] 100 55(11) 100 + + + + I/H 42 N Y ↑ Y N
[29] 125 76(ng) 70 + + 96 Y ↑
[108] 165 57(11) 100 + + 69 ↑ 45 N
[68] 178 57(13) 59 + 68 N 24 N L/R N Y N
[45] 243 65(11) 89 + I/H L Anterior ↑ Y ↑
[19] 26 63(9) 100 + 100 58 N Y N
[78] 178 69(11) 67 + 100 36 N Y N
[38] 73 52(10) 100 + 80 43 L↑ Y N
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Table 3  Relation between the occurrence of post-stroke depressive symptoms  
and stroke characteristics
Ref n 
mean age/
range
(yrs(SD))
proportion
first-ever
stroke
(%) 
stroke – depressive 
symptoms 
assessment interval 
(months)
type of stroke (%) side (%)
posterior/anterior
part of the brain
size
(volume)
stroke severity* aphasia
<1 1-6 7-12 >12 infarction relation left relation left/right relation assessed relation assessed relation assessed relation
[62] 126 62(13) 100 + 88 42 N Y ↑
[58] 35 55-91 72 + 87 N Y N
[66] 202 75(ng) 88 + + 88 46 L/R
[103] 72 33-85 100 + I/H 51 N Y
[39] 145 18-93 75 + I/H 55 R↑ L/R Y ↑
[21] 436 75(12) 83 + + 86 49 N Y
[46] 47 24-79 100 + 88 68 L Anterior ↑ † Y N
[48] 20 53(9) 100 + I/H 45 L/R Anterior↑ Y N
[104] 148 62(ng) 100 + 85 N 54 N L/R N Y N
[41] 417 68(ng) 81 + I/H ng N L/R Anterior ↑ †
[59] 285 25-80 74 + 81 ng N Y N
[20] 161 67(13) 100 + + 85 ng N Y ↑
[47] 128 71(14) 100 + + 81 34 N L/R Anterior ↑
[36] 35 66(ng) 100 + I/H 54 L↑ R Both↑ Y ↑
[28] 48 59(ng) 100 + 46 L Anterior ↑ Y Y N
[55] 89 55(11) 100 + 100 42 Y ↑ Y N
[105] 60 71(11) 100 + I/H 52 N Y ↑
[34] 103 63(11) 74 + + + I/H 46 L↑ Y N
[27] 153 35-75 100 + + N
[106] 662 63(ng) 71 + I/H N 48 N Y N
[107] 50 51-89 100 + 22 N
[42] 421 72(8) 75 + I/H 34 L/R Both↑ † Y
[73] 192 62(13) 100 + 83 40 N Y N
[56] 100 55(11) 100 + + + + I/H 42 N Y ↑ Y N
[29] 125 76(ng) 70 + + 96 Y ↑
[108] 165 57(11) 100 + + 69 ↑ 45 N
[68] 178 57(13) 59 + 68 N 24 N L/R N Y N
[45] 243 65(11) 89 + I/H L Anterior ↑ Y ↑
[19] 26 63(9) 100 + 100 58 N Y N
[78] 178 69(11) 67 + 100 36 N Y N
[38] 73 52(10) 100 + 80 43 L↑ Y N
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Table 3  Continued
Ref n 
mean age/
range
(yrs(SD))
proportion
first-ever
stroke
(%) 
stroke – depressive 
symptoms 
assessment interval 
(months)
type of stroke (%) side (%)
posterior/anterior
part of the brain
size
(volume)
stroke severity* aphasia
<1 1-6 7-12 >12 infarction relation left relation left/right relation assessed relation assessed relation assessed relation
[57] 95 67(11) 100 + + 80 N 43 N Y N
[53] 93 37-86 100 + I/H 46 N L/R Anterior ↑ Y ↑
[63] 91 62(13) 100 + I/H N 43 N L/R N Y ↑ Y N
[23] 104 59(10) 100 + 78 N 49 N
[79] 452 67(12) 85 + 57 ng N Y ng
Empty cells: no assessment, ng: not given, Y: Yes, N: No, + indicates timing of post-stroke depressive 
symptoms assessment, I: Infarction, H: Haemorrhage, I/H: Infarction/ Haemorrhage proportion not given, 
L: Left hemisphere, R: Right hemisphere, L/R: Left/Right lesion proportion not given,* assessed by IHSS 
(National Institute of Health Stroke Scale) or SSS (Scandinavian Stroke Scale), A: Anterior part of the brain, 
Table 4 Relation between occurrence of post-stroke depression/depressive  
 symptoms and pre-stroke neuroimaging characteristics
Depression
Ref
n
mean
age/range
(yrs (SD))
proportion
first-ever
stroke
(%)
stroke-depression
assessment interval
(months)
silent infarction WML MTA cortical atrophy
<1 1-6 7-12 >12 assessed relation assessed relation assessed relation assessed relation
[64] 70 70(ng) 100 + Y N Y N Y N
[60] 80 73(ng) 80 + Y ↑
[52] 275 71(7) 70 + Y N Y N Y N
[30] 189 69(12) 100 + + Y N Y N
Depressive 
symptoms
Ref
[62] 126 62(13) 100 + Y N Y N
[66] 202 75(ng) 88 + + Y Y N Y N
[65] 158 55-85 ng + Y N Y N Y N
[63] 91 62(13) 100 + Y N Y N
[67] 395 70(7) 79 + Y N
Empty cells: no assessment, ng: not given, Y: Yes, N: No, + indicates timing post-stroke depression/
depressive symptoms assessment, WML: White Matter Lesion, MTA: Medial Temporal Lobe Atrophy, 
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Table 3  Continued
Ref n 
mean age/
range
(yrs(SD))
proportion
first-ever
stroke
(%) 
stroke – depressive 
symptoms 
assessment interval 
(months)
type of stroke (%) side (%)
posterior/anterior
part of the brain
size
(volume)
stroke severity* aphasia
<1 1-6 7-12 >12 infarction relation left relation left/right relation assessed relation assessed relation assessed relation
[57] 95 67(11) 100 + + 80 N 43 N Y N
[53] 93 37-86 100 + I/H 46 N L/R Anterior ↑ Y ↑
[63] 91 62(13) 100 + I/H N 43 N L/R N Y ↑ Y N
[23] 104 59(10) 100 + 78 N 49 N
[79] 452 67(12) 85 + 57 ng N Y ng
P: Posterior part of the brain, † anterior/posterior cerebral artery, ↑ higher prevalence of post-stroke 
depressive symptoms among patients with a left sided stroke/anterior or posterior lesion/larger lesion 
volume/more severe stroke.
Table 4 Relation between occurrence of post-stroke depression/depressive  
 symptoms and pre-stroke neuroimaging characteristics
Depression
Ref
n
mean
age/range
(yrs (SD))
proportion
first-ever
stroke
(%)
stroke-depression
assessment interval
(months)
silent infarction WML MTA cortical atrophy
<1 1-6 7-12 >12 assessed relation assessed relation assessed relation assessed relation
[64] 70 70(ng) 100 + Y N Y N Y N
[60] 80 73(ng) 80 + Y ↑
[52] 275 71(7) 70 + Y N Y N Y N
[30] 189 69(12) 100 + + Y N Y N
Depressive 
symptoms
Ref
[62] 126 62(13) 100 + Y N Y N
[66] 202 75(ng) 88 + + Y Y N Y N
[65] 158 55-85 ng + Y N Y N Y N
[63] 91 62(13) 100 + Y N Y N
[67] 395 70(7) 79 + Y N
↑ higher prevalence of post-stroke depression among stroke patients with more atrophy.
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Table 5 Relation between occurrence of post-stroke depression and  
 demographic/(bio)psychological pre-and post-stroke characteristics 
                 Demographics                                                                                                Demographics
Pre-stroke
characteristic
Post-stroke
characteristics
Ref n
mean age/
range
(yrs(SD))
proportion
first-ever
stroke
 (%)
stroke-depression 
assessment interval
(months)
age sex education living alone
history of
depression/
psychiatric 
disease
physical
disability
cognitive
impairment
<1 1-6 7-12 >12
as
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ss
ed
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n
as
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ss
ed
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as
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ed
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n
[51] 159 67(ng) 75 + Y N Y female↑ Y low↑ Y Y N
[40] 273 64(16) 100 + + BI ↑
[72] 50 51(1) 100 + + Y Y female↑ Y Y N
[26] 80 44-100 80 + + + + Y Y ↑
[70] 52 60(12) 100 + Y N Y female↑ Y ↑ BI ↑ MMSE N
[109] 88 70(10) 76 + Y N Y female↑ Y N BI N MMSE ↑
[2] 49 69(ng) 70 + + Y N Y N Y N
[73] 94 70(ng) 52 + + Y N Y N Y N Y N BI ↑ MMSE N
[74] 60 >75 =45% 100 + Y older↑ Y N Y N Y N BI ↑ MMSE ↑
[44] 130 68(ng) 100 + Y N Y N Y N Y N
[43] 87 63(14) 68 + Y N Y N Y N Y N Y ↑ BI ↑ MMSE N
[50] 38 55(ng) 100 + Y N Y N Y N Y N JHFI N MMSE ↑
[49] 94 71(10) 73 + + Y N Y N Y N BI ↑ MMSE ↑
[54] 120 58(ng) 100 + Y N Y N Y N Y N Y N
[33] 141 56(ng) 83 + Y younger↑ Y N Y ↑ ADL N MMSE N
[32] 99 71(10) 76 + Y N Y N Y N Y N BI N MMSE N
[77] 190 69(12) 100 + Y Y N MMSE N
[52] 275 71(7) 70 + Y N Y N Y N Y N Y ↑ ADL ↑ MMSE N
[102] 149 81(5) 73 + Y N Y N
[30] 189 69(12) 100 + + Y N Y N Y N BI N
Empty cells: no assessment, ng: not given, Y: Yes, N: No, + indicates timing of post-stroke depression 
assessment, ↑ indicates higher prevalence of post-stroke depression among patients who were living 
alone/had a history of depression or psychiatric disease/had more post-stroke physical disability/
suffered from post-stroke cognitive impairment, BI: Barthel Index, JHFI: John Hopkins Functional  
Inventory, ADL: Activity Daily Living, MMSE: Mini Mental State.
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Table 5 Relation between occurrence of post-stroke depression and  
 demographic/(bio)psychological pre-and post-stroke characteristics 
                 Demographics                                                                                                Demographics
Pre-stroke
characteristic
Post-stroke
characteristics
Ref n
mean age/
range
(yrs(SD))
proportion
first-ever
stroke
 (%)
stroke-depression 
assessment interval
(months)
age sex education living alone
history of
depression/
psychiatric 
disease
physical
disability
cognitive
impairment
<1 1-6 7-12 >12
as
se
ss
ed
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[51] 159 67(ng) 75 + Y N Y female↑ Y low↑ Y Y N
[40] 273 64(16) 100 + + BI ↑
[72] 50 51(1) 100 + + Y Y female↑ Y Y N
[26] 80 44-100 80 + + + + Y Y ↑
[70] 52 60(12) 100 + Y N Y female↑ Y ↑ BI ↑ MMSE N
[109] 88 70(10) 76 + Y N Y female↑ Y N BI N MMSE ↑
[2] 49 69(ng) 70 + + Y N Y N Y N
[73] 94 70(ng) 52 + + Y N Y N Y N Y N BI ↑ MMSE N
[74] 60 >75 =45% 100 + Y older↑ Y N Y N Y N BI ↑ MMSE ↑
[44] 130 68(ng) 100 + Y N Y N Y N Y N
[43] 87 63(14) 68 + Y N Y N Y N Y N Y ↑ BI ↑ MMSE N
[50] 38 55(ng) 100 + Y N Y N Y N Y N JHFI N MMSE ↑
[49] 94 71(10) 73 + + Y N Y N Y N BI ↑ MMSE ↑
[54] 120 58(ng) 100 + Y N Y N Y N Y N Y N
[33] 141 56(ng) 83 + Y younger↑ Y N Y ↑ ADL N MMSE N
[32] 99 71(10) 76 + Y N Y N Y N Y N BI N MMSE N
[77] 190 69(12) 100 + Y Y N MMSE N
[52] 275 71(7) 70 + Y N Y N Y N Y N Y ↑ ADL ↑ MMSE N
[102] 149 81(5) 73 + Y N Y N
[30] 189 69(12) 100 + + Y N Y N Y N BI N
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Table 6  Relation between occurrence of post-stroke depressive symptoms and  
demographic/(bio)psychological pre-and post-stroke characteristics 
                 Demographics                                                                                                Demographics
Pre-stroke
characteristic
Post-stroke
characteristics
Ref n
mean age/
range
(yrs(SD))
 
proportion
first-ever
stroke
(%)
stroke-depressive 
symptoms 
assessment interval
(months)
age sex                                                          education living alone
history of
depression/
psychiatric
disease
physical
disability
cognitive
impairment
<1 1-6 7-12 >12
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[71] 196 15-49 100 + Y N Y N Y ↑ Y ↑ mRS ↑ MMSE
[62] 126 62(13) 100 + Y Y Y BI ↑ 6 
domains
↑
[66] 202 75(ng) 88 + + Y younger↑ Y Y Y ↑ mRS ↑
[103] 72 33-85 100 + Y Y female↑ Y N Y N BI
[39] 145 18-93 75 + Y younger↑ Y Y BI ↑
[21] 436 75(12) 83 + + Y Y female↑ Y Y Y ↑ FIM
[76] 40 63(ng) 82 + Y Y N QRS ↑ QRS ↑
[104] 148 62(ng) 100 + Y N Y N Y N BI ↑
[41] 417 68(ng) 81 + Y N Y N Y N BI ↑ GHQ ↑
[87] 508 66(12) 100 + Y age 45-85↑ Y female↑ Y high↑
[59] 285 69 (ng) 74 + Y N Y female↑ Y N Y ↑ Y ↑ BI N BCRS ↑
[20] 161 67(13) 100 + + Y older↑ Y female↑ Y ↑
[36] 35 66(ng) 100 + Y Y FIM ↑
[55] 89 55(11) 100 + Y older↑ Y N Y N Y N BI/mRS ↑
[110] 207 64(12) 100 + Y N Y female↑ Y N BI/mRS ↑
[106] 626 63(13) 71 + Y N Y N Y BI ↑
[42] 421 72(8) 75 + Y Y female↑ Y N Y N Y N BI ↑ MMSE ↑
[111] 119 61(12) 69 + Y N
[56] 100 55(11) 100 + + + + Y N Y N/male↑* Y N BI ↑ †
[29] 125 76(ng) 70 + + BI ↑ MMSE ↑
[75] 141 72(11) 84 + + Y Y Y Y ADL N ATM ↑
[108] 165 57(11) 100 + + Y N Y N Y N Y N ADL ↑ *
[68] 178 57(13) 59 + Y N Y female↑ Y ↑
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Table 6  Relation between occurrence of post-stroke depressive symptoms and  
demographic/(bio)psychological pre-and post-stroke characteristics 
                 Demographics                                                                                                Demographics
Pre-stroke
characteristic
Post-stroke
characteristics
Ref n
mean age/
range
(yrs(SD))
 
proportion
first-ever
stroke
(%)
stroke-depressive 
symptoms 
assessment interval
(months)
age sex                                                          education living alone
history of
depression/
psychiatric
disease
physical
disability
cognitive
impairment
<1 1-6 7-12 >12
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[71] 196 15-49 100 + Y N Y N Y ↑ Y ↑ mRS ↑ MMSE
[62] 126 62(13) 100 + Y Y Y BI ↑ 6 
domains
↑
[66] 202 75(ng) 88 + + Y younger↑ Y Y Y ↑ mRS ↑
[103] 72 33-85 100 + Y Y female↑ Y N Y N BI
[39] 145 18-93 75 + Y younger↑ Y Y BI ↑
[21] 436 75(12) 83 + + Y Y female↑ Y Y Y ↑ FIM
[76] 40 63(ng) 82 + Y Y N QRS ↑ QRS ↑
[104] 148 62(ng) 100 + Y N Y N Y N BI ↑
[41] 417 68(ng) 81 + Y N Y N Y N BI ↑ GHQ ↑
[87] 508 66(12) 100 + Y age 45-85↑ Y female↑ Y high↑
[59] 285 69 (ng) 74 + Y N Y female↑ Y N Y ↑ Y ↑ BI N BCRS ↑
[20] 161 67(13) 100 + + Y older↑ Y female↑ Y ↑
[36] 35 66(ng) 100 + Y Y FIM ↑
[55] 89 55(11) 100 + Y older↑ Y N Y N Y N BI/mRS ↑
[110] 207 64(12) 100 + Y N Y female↑ Y N BI/mRS ↑
[106] 626 63(13) 71 + Y N Y N Y BI ↑
[42] 421 72(8) 75 + Y Y female↑ Y N Y N Y N BI ↑ MMSE ↑
[111] 119 61(12) 69 + Y N
[56] 100 55(11) 100 + + + + Y N Y N/male↑* Y N BI ↑ †
[29] 125 76(ng) 70 + + BI ↑ MMSE ↑
[75] 141 72(11) 84 + + Y Y Y Y ADL N ATM ↑
[108] 165 57(11) 100 + + Y N Y N Y N Y N ADL ↑ *
[68] 178 57(13) 59 + Y N Y female↑ Y ↑
36
post-stroke cognitive impairment compared with those without (table 5, 6). In nine 
studies [77,43,78,70,32,73,33,52,79] (stroke survivors investigated n=1568, range 
n=52-452) this relation could not be identified. 
Discussion
Data from 107 studies were reviewed on frequency, time-course and risk factors of 
post-stroke depression/depressive symptoms (PSD/PSDS) in survivors, making it the 
largest review in this area. In part, some of this has also been addressed in previous 
reviews [4-6], however they often lacked detailed assessment of possible confounders 
chapter 2
Empty cells: no assessment, ng: indicates not given, Y: Yes, N: No, + indicates timing of post-stroke 
depressive symptoms assessment * only more than one year post-stroke, † relation only at six months 
post-stroke, ↑ indicates higher prevalence of post-stroke depression among patients who were living alone/
had a history of depression or psychiatric disease/had more post-stroke physical disability/suffered from 
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                 Demographics                                                                                                Demographics
Pre-stroke
characteristic
Post-stroke
characteristics
Ref n
mean age/
range
(yrs(SD))
 
proportion
first-ever
stroke
(%)
stroke-depressive 
symptoms 
assessment interval
(months)
age sex                                                               education living alone
history of
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[19] 26 63(9) 100 + Y N Y N
[69] 739 69(13) 88 + Y N Y N Y ↑ ADL ↑
[78] 178 69(11) 67 + Y N Y N Y N BI ↑ MMSE N
[38] 73 52(10) 100 + Y younger↑ Y Y Y FIM ↑
[57] 95 67(11) 100 + + Y Y Y BI ↑
[53] 93 37-86 100 + Y Y N Y ↑
[63] 91 62(13) 100 + Y N Y female↑ Y N MMSE ↑
[23] 104 59(10) 100 + Y N Y N BI ↑ PCRS ↑
[79] 452 67(12) 85 + Y N Y N MMSE N
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from pre-stroke (bio)psychological/neuroimaging characteristics in combination with 
post-stroke characteristics on the prevalence of PSD/PSDS. 
The prevalence of PSD/PSDS varied from 5% to 79% within one month after stroke, 
which showed a tendency to decline to 8% to 59% one year after stroke (table 1). 
Except for post-stroke physical/cognitive disability, there was no relation for post-stroke 
characteristics and PSD/PSDS. In addition, there was no relation for pre-stroke (bio)
psychological/neuroimaging characteristics (including age, sex, education, marital 
status, silent infarction, WML, medial temporal lobe atrophy, cortical atrophy) and 
PSD/PSDS. Whereas, psychiatric or depressive disorders in the medical history was 
significantly related with PSD/PSDS in most studies.
2
 post-stroke depressive symptoms 
post-stroke cognitive impairment, BI: Barthel Index, ADL: Activity Daily Living, mRS: modified Rankin Scale, 
FIM: Functional Independence Measure, QRS: Questionnaire on Resources and Stress, MMSE: Mini Mental 
State, GHQ: General Health Questionnaire, BCRS: Brief Cognitive Rating Scale, ATM: Abbreviated Mental 
Test.
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range
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[19] 26 63(9) 100 + Y N Y N
[69] 739 69(13) 88 + Y N Y N Y ↑ ADL ↑
[78] 178 69(11) 67 + Y N Y N Y N BI ↑ MMSE N
[38] 73 52(10) 100 + Y younger↑ Y Y Y FIM ↑
[57] 95 67(11) 100 + + Y Y Y BI ↑
[53] 93 37-86 100 + Y Y N Y ↑
[63] 91 62(13) 100 + Y N Y female↑ Y N MMSE ↑
[23] 104 59(10) 100 + Y N Y N BI ↑ PCRS ↑
[79] 452 67(12) 85 + Y N Y N MMSE N
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However, some methodological aspects must be considered. A proper identification 
of risk factors for any outcome requires structured and standardised assessment of 
that particular outcome. PSD and PSDS have been assessed with the aid of various 
diagnostic criteria (n=3) or tests (n=16) respectively, making comparisons difficult. 
Another kind of bias is the fact that multiple publications are based on virtually the 
same patient cohort; accordingly these results are not entirely based on different 
study populations (table 1). On the other hand it is almost impossible to exclude these 
“double counts” at the selection procedure on the basis of unambiguous in-or 
exclusion criteria as they share, for obvious reasons, the key word upon which 
selection was based. The sequential assessment of PSD/PSDS within studies has 
been performed in only 25 studies [30,59,26,80,72,27,20,21,47,81,82,83,32,84,22,85,
57,66,23,24,86] that used two different diagnostic criteria (DSM-III or IV) and eight 
different screening tools to assess PSD/PSDS each with different cut-offs and stroke 
- depression assessment intervals, which makes it difficult to estimate a reliable PSD/
PSDS time-course. In addition, these studies also differed in terms of patient inclusion 
(such as number of stroke survivors, first-ever versus ever stroke, stroke severity, 
post-stroke physical disability and post-stroke cognitive impairment), in the collection 
of pre-stroke neuroimaging data and (bio)psychological factors (such as age, sex, 
educational level, marital status and medical history of depression). For example, we 
found considerable a difference in age between the studies making comparisons 
difficult, as age is an important determinant of depression or depressive symptoms in 
a number of studies, but not all. [55,20,39,87,33,74,66]
In order to judge the external validity it is essential to have information on the proportion 
patients that has been included, relative to the stroke population of that particular 
hospital. Unfortunately, most studies do not report this information. Consequently, all 
studies report on patients who completed a neuropsychological examination. It seems 
likely that patients, who could not complete this, presumably had a larger stroke with 
more severe neurological deficits and suffered more often from aphasia than those who 
were examined. This could have led to an underestimation of PSD/PSDS. Another 
source of bias that may lead to underestimation of PSD/PSDS is the fact that all studies 
only included patients that were actually admitted to the hospital. Many stroke patients, 
especially the most severely affected, are not admitted to the hospital weeks after stroke 
and will not be included in studies investigating PSD/PSDS. It seems likely that they are 
the one with the highest prevalence of PSD/PSDS. On the other hand, people with only 
a minor stroke may not have been included since they, for example, were not willing to 
participate months after a stroke from which they had already completely recovered. 
Theoretically, this could have led to overestimation of PSD/PSDS.
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There are several pre-stroke factors, both biological-demographic as well as from the 
medical history that could, independent from the stroke, relate to PSD/PSDS. Such a 
confounder could be the presence of vascular white matter lesions, that due do its 
increased presence in stroke patients [88,89] and its relation with depressive 
symptoms in the elderly [61] fulfills the criterion of being a confounder. As pre-stroke 
assessment of depression/depressive symptoms is usually not possible for obvious 
reasons confounding by (unnoticed) pre-stroke presence or of other pre-stroke factors 
cannot be excluded. It could therefore be that the differential presence of white matter 
lesions determines who does and who does not develop PSD/PSDS. 
As originally stated by Alexopoulos when proposing his “vascular depression” 
hypothesis cerebrovascular disease can predispose, precipitate, or perpetuate a 
depressive syndrome in older adults. This means that it may the combination of 
pre-existent manifestation of cerebrovascular disease (including previous (silent) 
brain infarctions, vascular white matter lesions) and the acute stroke rather than the 
acute stroke itself alone that may be related to the emergence of post-stroke depressive 
symptoms. 
In order to assess the relative contribution of this preexistent cerebrovascular disease 
to the occurrence of post stroke depressive symptoms we reviewed the effect of 
pre-stroke neuroimaging variables (including white matter lesions and cerebral 
atrophy) on PSD/PSDS. However, one has to keep in mind that these characteristics 
were always rated on neuroimaging performed directly after the qualifying stroke. 
Although it seems unlikely, one cannot exclude the fact that early stroke signs (for 
example the appearance of hypodense areas on a CT) may be misclassified as a 
white matter lesions. As this misclassification is not related to our outcome (PSD/
PSDS), it will most likely be random and, if anything, result in reduced strength of an 
association between white matter lesions and PSD/PSDS. 
Our review shows that only very few studies take possibility of the existence of 
pre-stroke confounding factors into account. Only nine [30,60,62,63,52,64,65,66,67,67] 
out of 107 studies assessed their presence and no unequivocal interpretation could 
be made.
This systematic review clearly points out the methodological limitations and the lack 
of proof of a clear and predictable relation between stroke characteristics and the 
occurrence of a depressive episode. It seems therefore plausible that the size, site 
and severity of a stroke is not causally related to the occurrence of post-stroke 
depressive symptoms or post-stroke depression [4,6]. This can be understood by 
taking into consideration the anatomy of the mood regulation system. Anatomically 
this is a widespread system, involving the frontal lobe (particularly the subgenual 
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prefrontal cortex), the basal ganglia (particularly the caudate and putamen), the 
cerebellum, the hippocampus/amygdala complex, and possibly the temporal lobes 
[90]. It seems unlikely that a single vascular lesion would interrupt such a widely 
dispersed system to such an extent that it can result in a marked change in mood. 
This is in line with studies among elderly [91,92] that found a relation between 
depressive symptoms and WML or cerebral atrophy. This supports the idea that 
diffuse brain damage, rather than a focal insult, is related with depressive symptoms, 
possibly by widespread disruptions of the dispersed mood regulation system that 
may result in accompanying depressive symptoms.
Many studies, (including reviews) have described PSD/PSDS, but almost lacking 
uniform operationalisation of the outcome and not taken often occurring confounders 
into account. Our review indicates that, although PSD/PSDS may sound like an 
attractive concept, there is not much data based on sound methodological studies 
that support it. 
However, there may be no clear proof of a causal relation between stroke and the 
occurrence of depression or depressive symptoms, from a clinical point of view it is 
important to identify prognostic factors that could help in early identification of stroke 
patients at risk for PSD/PSDS. It is known that a previous depressive episode or a 
previous psychiatric disorder indicates vulnerability for future depression. Any 
life-event, not only being a stroke, could therefore increase the risk for depression 
among those patients [93-95]. This systematic review shows indeed that the presence 
of psychiatric or depressive disorders in the medical history is associated with an 
increased presence of PSD/PSDS. 
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2.2  Post-stroke depressive symptoms are associated 
with post-stroke characteristics
Abstract
Several studies have described the frequency and risk factors of post-stroke 
depressive symptoms (PSDS). However, most studies did not exclude patients with 
depressive symptoms shortly before stroke and paid little attention to pre-stroke risk 
factors of depression, including previous depressive episodes, white matter lesions, 
and brain atrophy. These are potential limitations to assess the true effect of stroke on 
the occurrence of depressive symptoms. Our aim was to investigate the prevalence 
and risk factors of PSDS with adjustments for the previously mentioned pre-stroke 
factors. Patients (n=420) with an acute clinical symptomatic TIA or cerebral infarction 
were eligible for enrolment in this study. The presence of PSDS was rated by the 
Hospital Anxiety Depression Scale 6-8 weeks post-stroke. The relation between (pre-) 
stroke factors and PSDS was assessed with multivariate regression analysis. 
The prevalence of PSDS was 13% and did not differ between stroke subtype or 
first-ever/ever occurrence of stroke. Higher degree of post-stroke handicap was 
related with PSDS (OR 5.39; 95% CI 2.40-12.08) and more functional independence 
had a protective effect of PSDS (OR 0.88; 95% CI 0.77-1.00). 
This is the largest study that investigated the prevalence and risk factors of PSDS by 
carefully excluded patients with depressive symptoms shortly before stroke. PSDS 
were not related to lesion side or location, but to the degree of post-stroke handicap 
and functional independence. Early detection of PSDS and its risk factors might help 
to predict long-term outcome and could promote early interventions of (behavioural) 
rehabilitation treatment strategies.
Liselore Snaphaan, Sieberen van der Werf, Karin Kanselaar and Frank-Erik de Leeuw. 
Depressive symptoms early after stroke are associated with pre-and post-stroke 
characteristics. Cerebrovasc Dis. Oct 2009,28:551-557
chapter 2
49
Post-stroke depressive symptoms (PSDS) frequently occur and interfere with 
successful stroke recovery.[1;2] The prevalence of post-stroke depressive symptoms 
(PSDS) varies between 11% to 78%. [3;4] These large differences are partly due to 
methodological differences between studies such as the use of different rating scales 
of depressive symptoms and different time intervals of stroke – depressive symptoms 
assessment. Another explanation is the inclusion of patients that already have 
depressive symptoms at the time of stroke. The high prevalence of depressive 
symptoms, between 8% and 16%, in the general elderly population [5]  may affect the 
prevalence of PSDS, that is at least for this part, not related to the stroke itself. 
There is an ongoing debate with respect to the possible causes of PSDS; some 
investigators stress a biomedical explanation, analogous to for example a hemi-paresis 
after an infarct in the pyramidal tract, [6] while others view PSDS secondary as a 
reaction to a threatening major life event [7] and loss of functional independence. [8] 
Investigating patients with a TIA may help in this respect by disentangling these stroke 
related factors for PSDS from other factors, as patients with a TIA have shorter duration 
of symptoms with complete functional recovery to pre-TIA functioning within 24 hours 
and in most cases without any visible lesion on neuroimaging. 
In addition, the relation between stroke and the occurrence of PSDS may be obscured 
by risk factors related to the stroke (such as type of stroke, lesion location, severity of 
clinical symptoms and post-stroke degree of disability) and by factors that were 
presumably already present before the stroke. We aimed at disentangling the effect of 
symptom duration and severity on the prevalence of PSDS by comparing this between 
TIA and ischemic stroke patients. In addition, it is known that depressive symptoms 
are related to vascular white matter lesions, cerebral atrophy or cognitive impairment, 
irrespective of a stroke. [9-11] Since white matter lesions are more prevalent among 
stroke patients [12] they may, at least in part, explain the increased prevalence of 
depressive symptoms. Although, few studies [13] adjust for stroke related risk factors, 
there are virtually no studies taking pre-stroke confounding factors (such as white 
matter lesions, cerebral atrophy and the presence of previous depressive episodes in 
the medical history) into account. 
We investigated, in one of the largest stroke cohorts (n=420) thus far, the prevalence 
of depressive symptoms 6-8 weeks after stroke by careful excluding patients with 
depressive symptoms in the months before the index stroke. We hypothesised that 
the prevalence of PSDS would be lower following TIA than cerebral infarction. We also 
aimed to identify risk factors for PSDS using multivariate models to take both pre- and 
post-stroke risk factors into account.
2
 post-stroke depressive symptoms 
50
Materials and Methods
Study population
Consecutive patients that presented with acute symptomatic cerebral ischemia 
(including TIA and cerebral infarction) according to the WHO diagnostic criteria, [14] 
and who were admitted to the Neurology department of the Radboud University 
Nijmegen Medical Centre, the Netherlands between October 2004 and July 2008 
were eligible for enrolment in the prospective Nijmegen Stroke Study. The Nijmegen 
Stroke Study prospectively investigates short- and long-term consequences of stroke 
with regular pre-planned assessments after stroke. Exclusion criteria for enrolment in 
this study were: intracerebral haemorrhage (n=84), death at the preplanned 
ascertainment time of depressive symptoms (n=41, 6-8 weeks after the qualifying 
stroke), not able to visit the hospital 6-8 weeks post-stroke due to physical limitations, 
patients with terminal diseases such as cancer but also chronic diseases (such as 
Parkinson disease, Alzheimer disease, dementia) were excluded even as patients 
with epileptic seizures, myocardial infarction or head trauma. The local medical ethics 
committee of the Arnhem Nijmegen region approved the study.
Diagnosis of cerebral ischemia was based on the presence of acute neurological 
symptoms that could only be explained by a vascular event in a specific arterial territory 
with a duration of < 24 hours (TIA) or > 24 hours (cerebral infarction) and verified by CT 
or MRI within the first week after the event. Cerebral ischemia was further subdivided in 
first-ever (i.e. occurring in patients either without previous clinical cerebral ischemia 
according to a structured questionnaire nor without ischemic lesions other than the 
corresponding lesion of the qualifying cerebral ischemia on CT/MRI) and ever cerebral 
ischemia (defined as patients with a history of previous cerebral ischemia according to 
a structured questionnaire with or without corresponding ischemic lesions on CT/MRI). 
Assessment of depressive symptoms
Six to eight weeks post-stroke patients rated the presence and severity of depressive 
symptoms on the Hospital Anxiety Depression Scale (HADS). [15] This screening 
instrument is well-validated in stroke patients. [16]  Every patient was checked on their 
visual acuity, capability of reading and understanding of the questionnaire. A score > 
8 on the depression subscale of the HADS was considered indicative for the presence 
of depressive symptoms and has been found to correlate highly with a formal diagnosis 
of a depression based on DSM-IV criteria. [16-18] 
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Assessment of possible pre-stroke risk factors 
Standardised structured questionnaires were used to obtain information about age, 
gender, martial status, educational level (i.e Dutch classification system according to 
Verhage [19], ranging in ascending order from 1 (less than primary school) to 7 
(university degree)). The presence of depressive symptoms in the medical history was 
assessed with the aid of a standardised, structured questionnaire that has been proven 
reliable and valid in other epidemiological studies. [11] This questionnaire identifies the 
occurrence depressive episodes before the stroke and whether the episodes had 
prompted the patients to seek medical advice. A positive “history of depressive 
symptoms” was defined as the occurrence of depressive episodes that had required 
attention of a general practitioner, psychologist, or psychiatrist; patients with depressive 
symptoms within 1 month before the qualifying stroke were excluded. 
White matter lesions (WML) were rated semiquantitative (0-3) according to the Age 
Related White Matter Changes-scale. [20] Cortical atrophy was defined as the mean 
width of the left and right Sylvian fissure divided by the maximum brain width (at the 
pineal level). [21] Subcortical atrophy was defined as the mean ventricle-to-brain ratio 
at the frontal, bicaudate and occipital level. [21]
Assessment of possible stroke-related risk factors 
The side of a stroke or TIA was judged on the basis of the acute clinical neurological 
symptoms at admission (classified as left or right hemispheric stroke or infratentorial 
stroke (i.e cerebellum or brainstem). Stroke severity was assessed at admission with 
the National Institute of Health Stroke Scale (NIHSS). [22] The location of lesions 
(classified as cortical, subcortical white matter, basal ganglia, thalamus, and 
infratentorial) was scored by an experienced stroke neurologist (FEdL) according to a 
standard procedure using neuroimaging (either CT or MRI) at which symptomatic 
lesions were best visible. 
Global cognition (MMSE [23]), functional status (Barthel Index (BI) [24][Mahoney and 
Barthel 1965] ranging from 0 (completely dependent) to 20 (completely independent)) 
and the degree of handicap (modified Rankin Scale (mRS) [25] ranging from 0 (no 
symptoms) to 5 (severe disability)) were assessed 6-8 weeks post-stroke. Patients 
with a mRS 0-1 were classified as 'favourable outcome'. those with with a mRS ≥2 were 
classified as 'unfavourable'. 
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Statistical Analysis
Two-sample t-tests were used for group comparisons of continuous data, Pearson 
Chi Square and Mann Whitney U testing were used for nominal (dichotomised variables 
i.e gender) and for ordinal data (for more than 2 outcome variables i.e education), 
respectively. All tests were two-tailed with the results considered significant at p<0.05. 
The relation between the PSDS (defined as a HADS > 8) and each individual pre- and 
post-stroke risk factor separately was assessed with age and sex adjusted logistic 
regression analysis. Subsequently, the predictor variables that turned out to be 
significantly related in the age and sex adjusted logistic model were then introduced 
into a step-backward logistic regression (conditional) analysis to calculate independent 
risk factors for PSDS, presented as odds ratios (OR), with 95% confidence interval 
(95% CI). 
Results
The final study population consisted of 420 patients with cerebral ischemia (TIA n=137 
and infarction n=283) with a mean age of 64.3 years (SD 14.0), a mean HADS 
depressive items score of 4.4 (SD 4.1) and 42% of them were female. The median 
educational level was 5 (high school level) and 24% of the patients were living alone 
(data not shown). 
Prevalence of PSDS
The overall prevalence of PSDS 6-8 weeks after stroke was 13% and varied between 
10% (TIA) to 15% (cerebral infarction) (table 1). There were 329 patients with a first-ever 
manifestation of stroke (TIA n=113 and cerebral infarction n=216) and 91 patients who 
had suffered a stroke before (TIA n=24 and cerebral infarction n=67). PSDS prevalence 
did not significantly differ across stroke subtypes (TIA versus cerebral infarction 
p=0.11) nor between first-ever and ever stroke with respect to PSDS (p=0.52, data not 
shown). 
Stroke related risk factors of PSDS
Patients with a higher MMSE score after stroke had a reduced risk for PSDS (OR 0.87; 
95% CI 0.80-0.94, per each point increase in the MMSE, table 2), as had patients with 
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less functional independency after stroke (OR 0.84; 95% CI 0.76-0.93, per each point 
increase in the Barthell index). Those with an unfavourable outcome (mRS ≥ 2) or with 
a more severe stroke had an increased risk for PSDS (OR 4.54; 95% CI 2.29-9.01 and 
OR 1.08; 95% CI 1.01-1.15, per point increase on the NIHSS, respectively, table 3). 
Pre-stroke risk factors of PSDS 
A pre-stroke history of depression was not a risk factor for PSDS at 6-8 weeks 
post-stroke (OR 1.02; 95% CI 0.37-2.85), as there were no other pre-stroke risk factors 
for PSDS. 
Multivariate model
 
The variables, in the age and sex adjusted logistic regression model, that turned out 
to be significantly related with PSDS (bold in table 2), were then introduced into a 
step-backward regression analysis to calculate predictors of PSDS. Unfavourable 
outcome (mRS ≥ 2) was related with an increased risk of PSDS (OR 2.46; 95% CI 
1.12-5.38), whereas more functional independency had a protective effect on PSDS 
(OR 0.88; 95% CI 0.77-1.00 per each point increase on the post-stroke BI). There was 
no significant relation between pre-stroke predictors and PSDS in multivariate 
models. 
Discussion
The prevalence of PSDS was 13% six to eight weeks post-stroke; there were neither 
significant differences between stroke subtypes with respect to the prevalence of 
PSDS nor for first-ever or ever stroke patients. Although others have investigated the 
frequency and predictors of PSDS, [3;13;26;27] this is the largest hospital based 
study (n=420), that in addition explicitly excluded patients with depressive symptoms 
in the weeks before stroke in order to obtain unbiased prevalence figures. Another 
novel aspect was that risk factors for PSDS were calculated with adjustments for 
possible pre- and post-stroke risk factors. A higher degree of post-stroke handicap 
and less post-stroke functional independency, independent from each other as well 
as from other risk factors, were related with an increased risk of PSDS.
A methodological aspect that should be noted is the possible selection bias. 
Non-responders in our study were  significantly more TIA patients. As TIA patients, by 
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Table 1  Patients’ characteristics classified by type of stroke and by presence or  
absence of post-stroke depressive symptoms
TIA n=137                                                                                           Cerebral infarction n=283 Total study population n=420 
post-stroke depressive
symptoms
post-stroke depressive 
symptoms
post-stroke depressive
symptoms
Present
(10%)
Absent
(90%) P-value
Present
 (15%)
Absent
(85%) P-value
Present
 (13%)
Absent
(87%) P-value
Characteristics
Demographics
Age mean (SD) 61.5(9.7) 61.2(13.7) 0.95 64.9(13.1) 65.9(14.3) 0.67 64.1(12.4) 64.3(14.3) 0.92*
Female gender (%) 31 34 0.81 51 44 0.40 46 41 0.42†
Living alone (%) 23 15 0.47 36 27 0.27 33 23 0.14†
Education median (range) 5(4-6) 5(2-7) 0.53 4(1-7) 5(1-7) <0.01 5(1-7) 5(1-7) <0.01‡
Post-stroke characteristics
Behavioural
Depressive Items mean (SD) 12.3(3.0) 2.8(2.5) <0.01 12.7(3.2) 3.4(2.5) <0.01 12.6(3.1) 3.2(2.5) <0.01*
MMSE mean (SD) 27.8(2.4) 28.4(1.8) 0.23 25.2(4.3) 26.9(3.3) <0.01 25.9(4.0) 27.4(2.9) <0.01*
Clinical
Barthel Index median (range) 20(-) 20(16-20) 0.76 20(4-20) 20(4-20) <0.01 20(4-20) 20(4-20) <0.01*
Rankin Scale median (range) 0(-) 0(-) na 2(0-5) 1(0-4) <0.01 1(0-5) 0(0-4) <0.01‡
NIHSS median (range) 0(-) 0(-) na 3(0-19) 3(0-27) 0.06 3(0-19) 2(0-27) 0.02*
First-ever stroke (%) 92 81 0.31 70 77 0.28 75 79 0.54†
Left/Right/Infratentorial (%) ** 46/39/15 46/47/7 0.50 50/38/12 41/44/15 0.58 46/38/13 43/45/12 0.63†
Neuroimaging
Cortical/Subcortical/Both/Infratentorial (%) - - na 7/38/41/14 16/48/26/10 0.26 9/41/38/12 18/48/25/9 0.33†
Subcortical structures
White matter/Basal ganglia/Thalamus (%) - - na 91/0/9 74/15/11 0.35 92/0/8 76/13/11 0.34†
Pre-stroke characteristics
History depressive symptoms (%) 0 17 0.14 24 14 0.23 16 15 0.92†
Mean grade subcortical atrophy (SD) § 0.3(0.04) 0.3(0.03) 0.53 0.3(0.04) 0.3(0.04) 0.59 0.3(0.04) 0.3(0.04) 0.75*
Mean grade cortical atrophy(SD) II 0.1(0.03) 0.1(0.02) 0.23 0.1(0.03) 0.1(0.03) 0.27 0.1(0.03) 0.1(0.03) 0.12*
ARWMC median (range) 0(0-12) 0(0-26) 0.99 0(0-12) 0(0-29) 0.42 0(0-12) 0(0-29) 0.48*
Age and sex adjusted differences between absence or presence of PSDS, were P-values were calculated 
by * Univariate t-test (continue data), † Pearson Chi-square analyses (categorical data), ‡ Mann-Whitney 
U Test (ordinal data); significant values (p < 0.05) are printed bold; § mean of ventricle to brain ratio at the 
frontal, bicaudate or occipital level; II mean width of the left and right sylvian fissure divided by the 
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Table 1  Patients’ characteristics classified by type of stroke and by presence or  
absence of post-stroke depressive symptoms
TIA n=137                                                                                           Cerebral infarction n=283 Total study population n=420 
post-stroke depressive
symptoms
post-stroke depressive 
symptoms
post-stroke depressive
symptoms
Present
(10%)
Absent
(90%) P-value
Present
 (15%)
Absent
(85%) P-value
Present
 (13%)
Absent
(87%) P-value
Characteristics
Demographics
Age mean (SD) 61.5(9.7) 61.2(13.7) 0.95 64.9(13.1) 65.9(14.3) 0.67 64.1(12.4) 64.3(14.3) 0.92*
Female gender (%) 31 34 0.81 51 44 0.40 46 41 0.42†
Living alone (%) 23 15 0.47 36 27 0.27 33 23 0.14†
Education median (range) 5(4-6) 5(2-7) 0.53 4(1-7) 5(1-7) <0.01 5(1-7) 5(1-7) <0.01‡
Post-stroke characteristics
Behavioural
Depressive Items mean (SD) 12.3(3.0) 2.8(2.5) <0.01 12.7(3.2) 3.4(2.5) <0.01 12.6(3.1) 3.2(2.5) <0.01*
MMSE mean (SD) 27.8(2.4) 28.4(1.8) 0.23 25.2(4.3) 26.9(3.3) <0.01 25.9(4.0) 27.4(2.9) <0.01*
Clinical
Barthel Index median (range) 20(-) 20(16-20) 0.76 20(4-20) 20(4-20) <0.01 20(4-20) 20(4-20) <0.01*
Rankin Scale median (range) 0(-) 0(-) na 2(0-5) 1(0-4) <0.01 1(0-5) 0(0-4) <0.01‡
NIHSS median (range) 0(-) 0(-) na 3(0-19) 3(0-27) 0.06 3(0-19) 2(0-27) 0.02*
First-ever stroke (%) 92 81 0.31 70 77 0.28 75 79 0.54†
Left/Right/Infratentorial (%) ** 46/39/15 46/47/7 0.50 50/38/12 41/44/15 0.58 46/38/13 43/45/12 0.63†
Neuroimaging
Cortical/Subcortical/Both/Infratentorial (%) - - na 7/38/41/14 16/48/26/10 0.26 9/41/38/12 18/48/25/9 0.33†
Subcortical structures
White matter/Basal ganglia/Thalamus (%) - - na 91/0/9 74/15/11 0.35 92/0/8 76/13/11 0.34†
Pre-stroke characteristics
History depressive symptoms (%) 0 17 0.14 24 14 0.23 16 15 0.92†
Mean grade subcortical atrophy (SD) § 0.3(0.04) 0.3(0.03) 0.53 0.3(0.04) 0.3(0.04) 0.59 0.3(0.04) 0.3(0.04) 0.75*
Mean grade cortical atrophy(SD) II 0.1(0.03) 0.1(0.02) 0.23 0.1(0.03) 0.1(0.03) 0.27 0.1(0.03) 0.1(0.03) 0.12*
ARWMC median (range) 0(0-12) 0(0-26) 0.99 0(0-12) 0(0-29) 0.42 0(0-12) 0(0-29) 0.48*
maximum brain width (at the pineal level); na not applicable; ** refers to left or right hemisphere 
or infratentorial ischemia; - no (or little) visible lesions on MRI or CT scan.
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definition, had no post-stroke neurological deficits,  the prevalence for PSDS could 
therefore be an overestimation. On the other hand, we excluded patients with more 
severe neurological deficits including those who were physically not able to visit the 
hospital 6-8 weeks post-stroke that are likely to have more PSDS. In turn, this could 
have led to underestimation of PSDS. We therefore consider the prevalence of 13% as 
a small overestimation because we excluded more patients with TIA’s than patients 
with severe deficits. Although, we aimed to investigate pre-stroke neuroimaging 
variables (including WML and subcortical/cortical atrophy) in relation to PSDS, one 
has to keep in mind that neuroimaging was performed directly after the qualifying 
stroke. Therefore, one cannot fully exclude the fact that early stroke signs (for example 
the appearance of hypodense areas on a CT) may have been misclassified as WML. 
For this reason WML were not rated in areas in which the infarction was suspected. As 
this possible misclassification is not related to our outcome (PSDS), it will most likely 
be random and, if anything, result in reduced strength of an association between 
WML and PSDS.
Furthermore, it is known that several pharmacologic agents are associated with onset 
of depression including selective antihypertensive agents, cimetidine, indomethacin, 
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Table 2 Pre-and post-stroke risk factors for post-stroke depressive symptoms 
Cerebral 
infarction
Total study 
population
Characteristics n=283 n=420
Demographics
Age 1.00(0.97-1.02) 1.00(0.98-1.02)
Gender (reference male) 1.33(0.69-2.54) 1.27(0.72-2.23)
High education ≥ level 5 
(reference low education <5) 
0.50(0.24-1.05) 0.64(0.34-1.20)
Post-stroke Characteristics
MMSE 0.88(0.81-0.96) 0.87(0.80-0.94)
Barthel Index 0.84(0.76-0.93) 0.84(0.76-0.93)
Rankin Scale ≥ 2 (reference rankin scale <2) 4.50(2.45-8.26) 4.54(2.29-9.01)
NIHSS 1.07(0.99-1.15) 1.08(1.01-1.15)
Values are Odds Ratios (95% Confidence Intervals) adjusted for age and gender; significant OR are 
printed bold (p < 0.05).
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alcohol, barbiturates, stimulant withdrawal, corticosteroids. However, the prescription 
of most of these drugs were not changed before the assessment of PSDS making a 
relation with emerging PSDS less likely. If any, it seems likely that patients with PSDS 
have a higher usage of these previously mentioned drugs. Due to an expected power 
problem we could not adjust for all these individuals variables separately.
In favor of our study is that we have included both TIA patients and patients with cerebral 
infarction. Including TIA patients, with usually short lasting symptoms with complete 
functional recovery and without any visible lesion on neuroimaging, gave us the 
opportunity to investigate whether stroke related factors itself would be related to PSDS 
or that other, for example adaptive mechanisms to a life event could also play a role. 
In addition, most previous studies predominantly focused on the relation between 
PSDS and post-stroke characteristics, without appropriate control for possible 
pre-stroke confounding. Our study has taken possible pre- and post-stroke risk 
factors into account, by introducing them into a multivariate analysis.
The prevalence of PSDS obtained from our study are consistent with hospital and 
 rehabilitation-based cross-sectional data. However some studies found a higher 
prevalence of PSDS because of the use of a more sensitive, but less specific cut-off 
≤ 7 on the HADS to identify depressive symptoms. [28] Another reason for our 
prevalence at the lower end of the spectrum could be that in contrast to our study, 
most studies [8;28] did not attempt to exclude individuals that suffered from a 
depression or depressive symptoms just weeks before the qualifying stroke. It seems 
likely that the prevalence of PSDS will be increased by including these patients. Our 
study explicitly excluded patients with depressive symptoms at the time of the stroke 
and therefore we consider the 13% prevalence of post-stroke depressive symptoms 
as a reliable estimate. 
We hypothesised that the prevalence of PSDS would be lower among TIA patients than 
cerebral infarction as TIA’s experience (by definition) no functional loss, a factor we 
found to be related with PSDS. Our study, however, did not find such a difference. 
A methodological explanation could be that the response among TIA patients was 
related with more psychological complaints after stroke. In other words, the persistence 
of depressive or psychological symptoms after the TIA could be related with visiting our 
outpatient clinic, leading to selection bias. Particularly, as our response among TIA 
patients was lower (about 60%) than in stroke patients, this may have played a role.
Some found a relation between side of lesion (left/right hemisphere), [29] lesion 
location (subcortical/cortical) [30] and PSDS. However they used univariate analysis 
to investigate this relation and were not able to adjust for possible risk factors. As 
most other studies, [31] we did not find a relation between PSDS and lesion size/
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location or post-stroke physical disabilities. This seems plausible as anatomically the 
mood regulation system is a widespread system, involving the frontal lobe (particularly 
the subgenual prefrontal cortex), the basal ganglia (particularly the caudate and 
putamen), the cerebellum, the hippocampus/amygdala complex, and possibly the 
temporal lobes. It seems therefore unlikely that a single vascular lesion would interrupt 
such a widely dispersed system to such an extent that it can result in a marked change 
in mood. This is in line with studies among elderly [11;32] that found a relation between 
depressive symptoms and WML or cerebral atrophy and supports the idea that a 
more diffuse brain damage is related with depressive symptoms. Possibly by global 
diffuse disruptions of the connecting mood regulation fibre tracts that may result in 
accompanying mood dysfunction. Although, despite our large sample size, we must 
not ignore the fact that type II errors may play a role of not finding a relation between 
lesion size/location. 
Some investigators [6] found a relation between cerebral atrophy and depressive 
symptoms long after stroke (2-3 years), others [33] (including ours) did not found this 
relation weeks to months after stroke. It could be that cerebral atrophy among depressive 
stroke patients develops during time and that this relation becomes only apparent after 
longer (years) follow up. This explanation could also apply for WML, however studies 
investigating WML after stroke a risk factor for PSDS are scarce. Our study found no 
relation between WML and depressive symptoms early after stroke and to our knowledge 
no other studies found a relation between WML and PSDS thus far.
Furthermore, relatively little studies paid attention on pre-stroke characteristics (such 
as depressive symptoms in their medical history) when investigating risk factors for 
PSDS. We did not found a relation between history of depressive symptoms and 
PSDS. Although, some studies [34;35] did found a relation, they often lacked a 
description of how a history of depressive symptoms was defined and virtually no 
study reported on actions taken with patients that were depressive at the time of 
stroke. We defined “history of depressive symptoms” as those depressive episodes 
that had required attention of a general practitioner, psychologist, or psychiatrist [11] 
and patients with depressive symptoms just before the qualifying stroke were excluded 
to provide a reliable as possible prevalence of PSDS. It seems likely that patients with 
depressive symptoms just before their stroke, still had their depressive symptoms at 
the 6-8 weeks assessment after stroke. This might explain differences in the prevalence 
of PSDS between the above mentioned studies and ours. 
The main outcome of our study is that unfavourable outcome (mRS ≥ 2) and less 
functional independence (BI) both at 6-8 weeks post-stroke are risk factors for PSDS. 
The relationship between post-stroke functional impairment and PSDS is poorly 
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understood. [36] Some have argued that stroke patients may develop depressive 
symptoms as a psychological reaction to limited physical functioning [37] others 
speculate that depressive symptoms itself produce functional impairment as a result 
of fatigue, hopelessness, and diminished motivation [38] and a third point of view is 
that physical disabilities can both be a cause or a consequence of depressive 
symptoms. [39] 
For patients, caregivers and their therapists it is clinically important to identify 
prognostic factors for PSDS because these can interfere with successful stroke 
recovery. [1;2] Early detection of PSDS and associated factors might help to predict 
long-term outcome and could provide opportunities for early interventions, including 
(behavioural) rehabilitation treatment strategies. Prospective studies are needed to 
provide more insight in the time-course of PSDS and to identify which prognostic 
factors are associated with the persistence or development of PSDS in the 
long-term.
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3.1 Epidemiology of post-stroke cognitive dysfunction
Abstract
Post-stroke memory dysfunction is a prerequisite for the diagnosis of post-stroke 
dementia. This diagnosis is made within months after a stroke, apparently assuming 
a relatively stable course of the post-stroke memory function. Clinical experience 
added to anecdotal evidence from the literature suggests that post-stroke memory 
function may be reversible. The aim of the present study was to systematically review 
the available data on the time course of post-stroke memory function in non-demented 
stroke survivors. In addition, we wanted to investigate the role of (pre-)stroke 
characteristics on post-stroke memory function. We performed systematic literature 
search of PubMed, with the following medical subject heading (MeSH) terms: memory 
and stroke. The search strategy yielded 798 papers of which 65 fulfilled our inclusion 
criteria and went on to the data extraction stage. Five studies reported the prevalence 
of post-stroke memory dysfunction at different post-stroke intervals. The prevalence 
of post-stroke memory dysfunction varied from 23 to 55% three months post-stroke, 
which declined from 11 to 31% one year post-stroke. Larger stroke volume, pre-stroke 
medial temporal lobe atrophy and white matter lesions were related with decreased 
post-stroke memory function. Not all patients with post-stroke memory dysfunction 
three months after a stroke had memory dysfunction one year post-stroke. 
Consequently, not all criteria for the dementia diagnosis were fulfilled anymore. This 
may indicate that post-stroke dementia may be reversible in a substantial proportion 
of stroke patients. Preferably, standardised re-assessment of cognitive function 
should be performed in each patient diagnosed with PSD.  
Liselore Snaphaan and Frank-Erik de Leeuw. Post-stroke memory function in  
non-demented patients: a systematic review on frequency and neuroimaging correlates.  
Stroke, Jan 2008, 38:198-203
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Introduction
Post-stroke memory dysfunction (PMD) is, by definition, a prerequisite for the diagnosis 
of post-stroke dementia (PSD) or vascular dementia (VaD) [1], albeit not a prominent 
clinical feature of the post-stroke cognitive profile [2]. This diagnosis is made within 
months after a stroke [1, 3], apparently assuming a relatively stable course of PMD. 
This is in contrast to what is common in clinical practice, since the prevalence of PMD 
is known to vary from 50% within the first few weeks after a stroke, gradually decreasing 
to 12% six months after a stroke [4, 5]. The presence of PMD is required to fulfill 
clinical diagnostic criteria for dementia. This may suggest that post-stroke dementia 
may be reversible in a substantial proportion of stroke patients that initially have been 
diagnosed with PSD.
Surprisingly, formal studies investigating the time course of post-stroke memory 
function (PMF) are scarce. This may allow for potential misclassification of post-stroke 
dementia or VaD when memory function changes over time (the presence of memory 
dysfunction is a symptom needed to fulfill this clinical diagnosis). 
Another reason for investigating the true occurrence of PMD is that a stroke only 
seldom occurs in the brain structure that is predominantly involved in memory 
encoding and retrieval (the medial temporal lobe) [6-8]. Despite this, the frequency of 
PSD or VaD is estimated to be over 30% [9], which may suggest that other (pre-)
stroke characteristics are related to post-stroke memory function (PMF) such as white 
matter lesions (WML), medial temporal lobe atrophy (MTA), previous (silent) infarcts, 
and pre-stroke cognitive function. Many studies have investigated the epidemiology 
of PMF. However, some methodological limitations must be considered, including 
small sample size, inability to adjust for confounding factors and unclear operation-
alisation and description of the timing of assessment of memory function. Only a few 
addressed the role of stroke characteristics and that of the previously mentioned 
presumed pre-stroke characteristics in patients with PMD. It is important to know the 
course of PMF, since albeit the pre-eminent factor in the PSD and VaD diagnosis, it 
may not even be present (to the same extent) over three months after the stroke, as it 
was during the diagnosis of PSD and VaD (within three months after stroke).
We systematically reviewed the available data on frequency, time course and risk factors 
of post-stroke memory function in non-demented stroke survivors. Secondly, we 
evaluated the effect of location and severity of stroke on PMF. In addition, we wanted to 
investigate the role of pre-stroke structural brain changes including WML, MTA, previous 
(silent) infarcts and pre-stroke cognitive decline on the frequency of PMF. 
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Methods 
A literature search of the electronic database PubMed was performed at 03-05-2006. 
We entered the following medical subject heading (MeSH) terms and text words in full 
and truncated: memory and stroke. In accordance with the literature the term stroke 
includes both cerebral infarcts and intracerebral haemorrhages. The search was 
limited to the English language, and included human studies with participants of 45 
years of age or over. We followed a two-step approach in this selection of eligible 
articles (see figure). First, one reviewer (LS) screened the abstracts for the following 
characteristics: (1) original paper, published in English on case-control or cohort 
studies (sample size had to be at least 15), and (2) information about memory and 
stroke had to be present. From screen positive abstracts full papers were collected 
that then went to a second selection step to identify papers that fulfilled the following 
inclusion criteria; (3) description and operationalisation of post-stroke memory 
function; (4) description of the stroke (at least one of the following characteristics had 
to be present: location, severity and first-ever stroke); (5) description of presumed 
pre-stroke factors that could possibly influence post-stroke memory (WML, previous 
stroke, MTA and pre-stroke cognitive function). Papers were evaluated against the 
inclusion criteria by two authors independent from each other (LS and FEdL); in case 
of disagreement a consensus meeting was held.
Results 
The search strategy yielded 798 papers. After screening of the title and the abstracts, 
101 papers were retrieved full-text and examined against the in- and exclusion criteria, 
of which 65 were included and went on to the data extraction stage (figure 1). 
Time course of post-stroke memory function 
The most common tests that were used to assess verbal memory function were: the 
Wechsler Memory Scale (WMS) [10], the Rey Auditory Verbal Learning Test (RAVLT) 
[11], the Rivermead Behavioural Memory Test (RBMT) [12], the Cambridge Assessment 
Of Mental Disorders (CAMCOG) [13], the California Verbal Learning Test (CVLT) [14], 
and the Verbal Learning Task (VLT) [15]. 
Five studies [16-19] investigated the formal time course of post-stroke memory 
dysfunction, that had all included first-ever stroke patients, at different post-stroke 
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intervals (table 1). There was a general tendency [20-34] of a reduced (verbal) memory 
function (table 2) among stroke survivors as compared to controls (healthy controls or 
normative data). 
There were ten studies that attempted to operationalise PMD, each with their own 
defined cut-offs (see details table 1) [4, 5, 16-19, 35-38].
The prevalence of PMD ranged from 50% weeks after the stroke to 11% more than a 
year after the stroke (see for details table 1). 
Relation between post-stroke memory function and stroke characteristics 
Table 2 presents an overview of post-stroke memory function (assessed at different 
stroke – memory assessment intervals) in relation to possible (pre-) stroke confounding 
factors.
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Step 1 Step 1 
 
  
 
101 included based on  
inclusion criteria 1 and 2   
798 abstracts were retrieved from 
search on Memory and Stroke  
697 excluded on the basis of 
the abstract  
65 articles included for data 
extraction on the basis of 
inclusion criteria 3-5 
 
36 articles were excluded on the 
basis of inclusion criteria 3-5 
Step 2 Step 2 
Figure 1  The stepwise approach in the selection of eligible and included 
articles
68
Several studies provided a clear description of the size (volume) [26, 39-43] and the 
location [4, 16, 25, 33, 34, 38, 42-51] of the infarction, however the relation with PMF 
was only seldom investigated. In one study [42] a linear relation between the size of 
the infarction and the degree of PMF was found. More circumstantial evidence for a 
role of stroke severity with respect to PMF comes from a study [41] that found a larger 
total volume of infarction among those patients who developed post-stroke 
dementia. 
Cerebral infarcts in the left middle temporal gyrus and the and/or left dorsal lateral 
frontal cortex were significantly correlated with PMF [46]. Four studies [33, 38, 44, 48] 
found a lower PMF in left-sided stroke compared to right hemispheric stroke. Most 
studies found left hemispheric stroke to be related to more severe PMD as compared 
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Table 1 Prevalence of post-stroke memory dysfunction: a time-course
  
Stroke survivors Prevalence of post-stroke memory dysfunction
Single memory assessment Number Mean age
yrs(SD)
First-ever
stroke
Memory 
test
Cut-off stroke – memory assessment interval
(months)
Ref 0.25 1 3 6 7 12 >12
4 16 59(NS) Y AVLT < 10 percentile 50%
37 78 NS NS RBMT Score failed 7 or 
more items
49%
38 220 59(13) NS WMS <2SD 23%
35 30 76(8) NS WMS < 1SD 50%
36 229 56(11) Y AVLT <15 percentile 31%
Multiple memory assessment
Ref
18 196 69(13) Y AVLT < 10 percentile 24% 17% 15%
5 139 69(12) Y AVLT < 10 percentile 22% 12%
16 60 61(NS) Y WMS NS 55% 31%
19 23 56(16) Y AVLT < 2SD 13% 11%
17 111 60(14) Y AVLT Z-Score < -1.65 22% 6%
Verbal memory tests Abbreviation    
AVLT: Auditory Verbal earning Test NS: Not Specified
RBMT: Rivermead Behavioural Memory Test Empty cells indicate no assessment 
WMS: Wechsler Memory Scal Y: Yes
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to the right hemisphere, presumably since most memory tasks rely on intact language 
function. Although these studies also included non-verbal memory tasks.
Relation between pre-stroke characteristics and post-stroke memory function 
There are a number of factors that presumably were already present prior to the stroke 
(including WML [52-54], MTA [55, 56] previous (silent) infarcts, and pre-stroke cognitive 
decline), that could be related to PMF. Due to the fact that stroke patients usually did not 
have neuroimaging and/or neuropsychology before the actual stroke, the effects of 
these factors on PMD are difficult to disentangle from the direct stroke effects. Some 
studies tried to overcome this problem by making adjustments for WML and MTA.
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Table 1 Prevalence of post-stroke memory dysfunction: a time-course
  
Stroke survivors Prevalence of post-stroke memory dysfunction
Single memory assessment Number Mean age
yrs(SD)
First-ever
stroke
Memory 
test
Cut-off stroke – memory assessment interval
(months)
Ref 0.25 1 3 6 7 12 >12
4 16 59(NS) Y AVLT < 10 percentile 50%
37 78 NS NS RBMT Score failed 7 or 
more items
49%
38 220 59(13) NS WMS <2SD 23%
35 30 76(8) NS WMS < 1SD 50%
36 229 56(11) Y AVLT <15 percentile 31%
Multiple memory assessment
Ref
18 196 69(13) Y AVLT < 10 percentile 24% 17% 15%
5 139 69(12) Y AVLT < 10 percentile 22% 12%
16 60 61(NS) Y WMS NS 55% 31%
19 23 56(16) Y AVLT < 2SD 13% 11%
17 111 60(14) Y AVLT Z-Score < -1.65 22% 6%
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Table 2  The relation between post-stroke memory function and presumed pre-stroke  
and stroke characteristics 
 
Ref Study population Post-stroke memory function Stroke characteristics PMF related
 pre-stroke
characteristics
Index Number Mean age
 yrs(SD)
Control Number Mean age
 yrs(SD)
Memory test Performance on 
memory test 
compared to 
controls*
Location
(left 
side)
Size
(ml)
First-
ever
WML MTA Silent
stroke
1-3 4-7 >12
Stroke-memory 
assessment interval
 (months)
28 Stroke
(CIND)
41 66(10) Stroke 
(NCI)
62 64(8) WMS -
22 Stroke 96 80(4) Healthy 23 80(6) CAMCOG -† Y
30 Stroke 99 71(14) Healthy 99 70(NS) AVLT = 53% 100%
27 Stroke 238 70(8) Healthy 38 67(5) WMS =† 29 0% Y Y
26 Stroke 
(Moderate 
MTA)
54 74(7) Stroke
(no
MTA)
100 67(8) WMS(R) -† 0% Y Y
25 Stroke
2months 
PS
65 56(11) Same 
patients
27months 
PS
65 56(11) ALVT - 54%  92%
21 Stroke 40 65(11) Healthy 20 65(12) WMS(R) - 50%
34 Silent 
incident 
stroke
396 NS Healthy 619 71(7) VLT -† 1.3 Y Y Y
23 Stroke 53 75(7) Healthy 1171 72(7) AVLT -
31 Stroke 259 80(4) Healthy 66 80(4) CAMCOG(R) =
33 Stroke 22 55(NS) Healthy 15 53(6) WMS-R - 45%
20 Multiple 
Strokes
23 63(NS) Healthy 11 63(9) CVLT -
49 Stroke 25 61(9) Normative 
data
213 61(3) WMS(R) = 0% 100%
CVLT -
32 Stroke 227 71(8) Healthy 240 71(7) SRT -
71
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White Matter Lesions
WML was scored in only 5 out of 12 studies [17, 18, 22, 43, 47]. Their presence, as 
assessed by means of semi-quantitative rating scales, varied from 15% to 45%. 
In general there was a lower PMF among patients with WML compared to those 
without, with otherwise identical demographical and stroke characteristics. WML were 
associated with global cognitive impairment in stroke patients [22, 57, 58]. Independent 
of this finding, there was a significant association between left frontal WML volume 
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Table 2  Continued 
 
Ref Study population Post-stroke memory function Stroke characteristics PMF related
 pre-stroke
characteristics
Index Number Mean age
 yrs(SD)
Control Number Mean age
 yrs(SD)
Memory test Performance on 
memory test 
compared to 
controls*
Location
(left 
side)
Size
(ml)
First-
ever
WML MTA Silent
stroke
1-3 4-7 >12
Stroke-memory 
assessment interval
 (months)
24 Stroke 198 68(12) Healthy 242 65(14) VLT - 86%
29 Stroke 123 72(9) Healthy 78 71(6) WMS(R) -† -† Y
Verbal memory tests Abbreviation    
WMS(R): Wechsler Memory Scale(Revised) WML: White Matter Lesions 
CAMCOG(R): Cambridge Assessment of Mental Disorders(Revised) MTA: Medial Temporal lobe Atrophy   
(R)AVLT: (Rey)Auditory Verbal earning Test NCI: No Cognitive Impairment
CIND: Cognitive Impairment No Dementia   PS: Post-Stroke
CVLT: California Verbal Learning Test NS: Not Specified  
SRT: Selective Reminding Test The grey cells indicate the post-stroke time interval of memory function assessment 
VLT: Verbal Learning Task Empty cells indicate no assessment or not specified
 * - : indicates significantly worse performance compared to the controls   
 (as defined in the original article) 
 +   :  indicates significantly better performance compared to the controls 
 (as defined in the original article)
 =   : indicates equal performance compared to the controls 
 (as defined in the original article) 
 †   : adjusted for at least one of the confounding factors mentioned 
 Y   : Yes, indicates that the article describes one or more pre-stroke characteristics
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and post-stroke working memory and between both left and right temporal WML 
volumes and memory function (not otherwise specified) [22].
Medial temporal lobe atrophy
The degree of MTA was assessed in only two studies. Their presence (as assessed on 
a semi-quantitative scale) [59] was strongly related to immediate and delayed 
post-stroke memory function (not otherwise specified) among 260 stroke survivors 
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[26]. This is in line with findings among 22 stroke survivors, in which there was a 
relation between post-stroke verbal memory as assessed with the Verbal Learning 
Task and pre-stroke MTA [47].
Previous (silent) infarcts
Information on previous (silent) infarction was lacking in most studies. Twenty-one 
articles included first-ever stroke survivors and 44 articles included also patients with 
multiple strokes or did not specify this. One article related silent stroke to memory 
[34]. They found that silent infarctions located in the thalamus, were associated with a 
greater decline in memory performance (z-score=-0.50; 95% confidence interval, 
-0.87 to –0.13).
Pre-stroke cognition
None of the 65 included articles investigated pre-stroke cognition in relation with 
post-stroke memory function. 
Discussion
Data from 65 studies were reviewed. The prevalence of post-stroke memory 
dysfunction in non-demented stroke survivors varied from 13 to 50% weeks after the 
stroke, which declined to 11 to 31% one year (or more) after stroke (table 1). It could 
be that post-stroke dementia is reversible in some stroke patients that have initially 
been diagnosed with PSD. Preferably, standardised re-assessment of cognitive 
function should be performed in each patient diagnosed with PSD. Unfortunately, this 
is not part of current diagnostic criteria (DSMIV [60] or NINDS-AIREN [1]).  A 
prerequisite for the description of a reliable time course of PMD is the presence of a 
stable source population and a complete as possible follow-up, otherwise the 
prevalence may appear to decrease when cases (those with PMD) selectively die. 
However, some methodological aspects must be considered. The measurement of 
PMD at several post-stroke intervals was assessed in five studies [5, 16-19]. Therefore, 
the ascertainment of a time course of PMD prevalence relies on different studies that 
investigated PMD at different post-stroke intervals. However, these studies differed 
tremendously in terms of patient inclusion, assessment of memory function and in the 
collection of stroke and pre-stroke (imaging) characteristics.
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In addition, and not always explicitly mentioned, most studies included patients who 
were able to complete neuropsychological examination. As a consequence, patients 
who could not complete testing (with a presumably larger stroke than those who could 
be examined) and those with aphasia were not examined. This could have led to an 
underestimation of PMD. On the other hand, people with only a minor stroke may not 
have been included since they, for example, were not willing to participate months 
after a stroke from which they had completely recovered already.
Some studies [5, 18, 23, 25, 26, 34, 50, 58, 61] investigated patients derived from a 
larger cohort (also includes one population based study [34]) that apparently had 
manifestations of cerebral ischemia, either on a scan (in that case it was unclear 
whether the infarct had been symptomatic or not) or based on history taking. These 
results are most likely not to be compared with “recent” stroke patients since it seems 
likely that both stroke characteristics and memory function differ between early stroke 
survivors and “ever stroke” patients.
Another source of bias that may lead to underestimation of PMD is the fact that all 
studies only included patients that were actually admitted to the hospital. Many stroke 
patients, especially the most severely affected with presumably pre-stroke cognitive 
impairment or even dementia, are not admitted to the hospital. It seems likely that they 
are the one with the highest prevalence of PMD and the highest risk of PSD. Some 
studies excluded patients that appear demented immediately after stroke. 
Consequently, the remaining sample (that then does not encompass any demented 
patient) has a lower risk of developing PSD.
We found a considerable age difference between the studies making comparisons 
difficult, as age is an important determinant of memory [24, 38, 62]. In addition, age 
is an important determinant of both MTA and WML, the latter being one of the most 
important confounders or effect modifiers in the relation between stroke and PMD. 
The possibility that differences in MTA or WML underlie (at least in part) the observed 
differences of PMD between studies can therefore not be ruled out.
There was a wide variability in assessment of verbal memory function and the definition 
of memory dysfunction. From most studies the memory dysfunction (for example 
expressed as the number SD’s below the mean) could not be calculated due to lack 
of raw data. Therefore the prevalence of PMD across different post-stroke intervals is 
rather limited and difficult to compare. Others studies used normative data or controls 
to define memory function. However, the problem with normative data could be that 
there is not much known about the persons investigated and they certainly did not 
undergo neuroimaging. Therefore, normative data could also include people with a 
silent stroke or white matter lesions. 
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The above mentioned methodological considerations may lead to questioning the 
validity of the concept of PMD and consequently of the diagnosis of VaD and PSD. 
These diagnoses are based (analogous to the diagnosis of Alzheimer’s disease) on 
the assumption of a stable or gradual decline of post-stroke memory function among 
patients without pre-stroke characteristics that could be related to PMD [1, 9]. Our 
review indicates that this is not true. Patients with PMD three months after a stroke 
(who could then have been diagnosed with VaD or PSD when also all other dementia 
criteria were fulfilled) could very well have recovery of memory dysfunction half a year 
after the stroke, and consequently not fulfill dementia diagnosis anymore. We also 
found that patients with PMD appear to constitute a population with many other (pre-) 
stroke factors that could, independent from the stroke, be related to PMD, both 
structural as well cognitive. 
The development of PMD also seems counter intuitive, since the stroke does usually 
not affect structures known to be involved in memory [6-8]. However, the emergence 
of post-stroke memory dysfunction fits in current thinking of memory as a function of 
an intact cerebral network, connecting several parts of the brain, including medial 
temporal lobes, anterior thalamic nucleus, mammillary body, fornix, and the prefrontal 
cortex which each other (the so called circuit of Papez) [4, 33, 34, 43, 46, 47, 63]. Any 
stroke in either these structures or in the connections in between could result in PMD. 
Presumably, patients with already preexisting damage in either compartments of the 
network (MTA) or in the connections (WML) are at increased risk for PMD. Perhaps 
these are also the patients who are therefore at the highest risk for PSD, although 
formal studies are lacking. Therefore, future studies should include well characterized 
stroke patients (both in terms of stroke and pre-stroke characteristics) that assess 
memory function at several predefined post-stroke intervals. They should particularly 
include information on whether an ever or first-ever stroke survivors are included since 
a previous stroke may influence cognitive function assessed immediately after another, 
novel stroke. Care should be given to proper registration of those patients that cannot 
complete memory testing. Novel imaging techniques such as task related, but also 
resting state fMRI may be of use in the detection of what part of the brain (or what 
network) shows altered function in patients with PMD. These techniques could then, 
when established, perhaps also be of use in the early prediction of those with PMD, or 
even post-stroke dementia and as such possibly guide early (cognitive) rehabilitation 
medicine.
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3.2  Memory performance after stroke associated with 
reduced medial temporal lobe functionality 
Abstract
Stroke is a leading cause of disability, not only because of motor limitations, but also 
because of the frequent occurrence of post-stroke cognitive impairment. This is 
illustrated by the fact that the risk of post-stroke dementia is reportedly higher than a 
recurrent stroke. The loss of subcortical and cortical functions in the post-stroke 
cognitive dysfunction spectrum is usually well explained by the size and location of 
the infarction. However, this does not apply for post-stroke memory dysfunction 
(especially episodic memory dysfunction), as there is almost never an infarction in the 
medial temporal lobe (MTL). Involvement of the MTL in post-stroke memory dysfunction 
seems likely since this structure is essential for memory encoding and retrieval. For a 
proper episodic memory function the MTL depends on intact connections with virtually 
the whole brain. Disconnection from other brain areas due to the infarction could lead 
to a reduced MTL function and the attendant reduced episodic memory function. We 
investigated MTL functionality in 28 first-ever stroke patients and 22 healthy controls 
with the aid of fMRI. Stoke patients with a reduced episodic memory function 6-8 
weeks after infarction had a reduced medial temporal lobe functionality. Post-stroke 
reduced MTL functionality may be responsible for the frequent observation of impaired 
post-stroke episodic memory function. Insight in this mechanism could be helpful in 
identifying which stroke patient may be at increased risk for developing post-stroke 
dementia and who could benefit from early cognitive rehabilitation. 
Liselore Snaphaan, Mark Rijpkema, Inge van Uden, Guillén Fernández, Frank-Erik de Leeuw. 
Reduced medial temporal lobe functionality in stroke patients: A functional Magnetic Resonance 
Imaging study. Brain. Jul 2009, 132:1882-8.
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Introduction
Stroke is a devastating disease that affects millions of people worldwide every year. It 
is a leading cause of disability; in the acute phase this is predominantly determined 
by limitations of motor function that usually show a fairly good tendency to recover in 
the first weeks, whereas in the subacute and chronic phase post-stroke cognitive 
impairment is an important determinant of recovery [Hofgren et al. 2007]. Cognitive 
impairment within the first month after stroke affects up to 10-82% [Rasquin et al. 
2004] of stroke survivors that surprisingly often goes unnoticed by treating physicians, 
usually due to a lack of a standardised assessment. The importance of post-stroke 
cognitive function as a major determinant of post-stroke Activity-of-Daily-Life (ADL) is 
illustrated by the fact that the risk of dementia after a stroke is reportedly higher than 
the risk of a recurrent stroke [Yokota et al. 2004]. 
Most of the spectrum of post-stroke cognitive dysfunction is usually well explained by 
the size and location of the infarction, whereas an explanation of the occurrence of 
memory dysfunction after stroke (especially episodic memory dysfunction) is currently 
lacking, as there is almost never an infarction in the medial temporal lobe (MTL) 
[Snaphaan and de Leeuw 2007]. Despite the absence of direct ischemic structural 
damage of the MTL, an impaired post-stroke function of the MTL presumably plays a 
role in the development of episodic memory dysfunction after stroke, as a proper MTL 
function is essential for memory encoding and retrieval [Brierley et al. 2002]. After all, for 
an optimal episodic memory function the MTL depends on intact connections with 
virtually the whole brain [Suzuki 2007]. Disconnection from these other brain areas due 
to the infarction could lead to a reduced MTL function and in addition to a  reduced 
episodic memory function. Therefore we hypothesised that the reduced episodic 
memory functionality found in stroke survivors is related with a reduced MTL function. 
The n-back task activates a so-called working memory (WM) network that consists of 
bilateral prefrontal cortex, parietal cortex, thalamus, anterior cingulate, and bilateral 
cerebellum [Callicott et al. 1999;Callicott et al. 2000]. In addition to these working 
memory related activations medial temporal deactivations were observed as well with 
the n-back task [Egan et al., 2003]. Previous studies showed that this deactivations can 
be used as a marker of the MTL function [Egan et al., 2003; Meyer-Lindenberg et al. 
2001;Weinberger et al. 1996]. The n-back task is a relatively simple task that can equally 
well be executed by patients with impaired episodic memory performance and controls, 
thereby excluding the possibility that differences in test performance (i.e n-back task) 
can explain differences in MTL activation. Consequently, the n-back task is used to 
assess functionality of the MTL in this study, but it is not a measure of episodic memory 
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performance. We investigated MTL activation by fMRI using the n-back task in 28 
consecutive first-ever supratentorial stroke survivors and 22 healthy controls. 
Methods
Patients
Patients were eligible for inclusion if they had an acute symptomatic first-ever 
supratentorial cerebral infarction between September 2005 and May 2007 and were 
admitted to the department of Neurology of the Radboud University Nijmegen Medical 
Centre. The diagnosis of stroke was based on both the presence of acute neurological 
symptoms that could only be explained by vascular lesion in a specific vascular 
territory and a compatible lesion on CT or MRI scan. Patients were excluded on the 
basis of the following criteria: age > 75 years, preexistent cognitive decline (considered 
present when the patient had a score of <78 on the short Informant Questionnaire on 
cognitive decline in elderly (IQCODE) [de Jonghe et al. 1997] ) or concurrent cognitive 
impairment (considered present when the patient had a score of ≤ 23 on the Mini 
Mental State examination (MMSE) [Folstein et al. 1973]), history of concomitant 
neurological disease, presence of diseases or the use of medication that were likely 
to affect cognition, history of alcohol or drug abuse, severe white matter lesions 
(operationalised as a score ≥ 2 in two or more regions as assessed with the ARWMC 
scale [Wahlund et al. 2001]), clinical or radiological evidence of a previous infarction, 
aphasia and MRI contra-indications (metal implants, pacemaker, claustrophobia). In 
total 52 patients fulfilled in- and exclusion criteria; 38 of them agreed to participate in 
the study (response 73%). There were no differences between responders and 
non-responders with respect to the baseline characteristics described in table 1. Ten 
of them were left out of the analysis because of distortion of MRI data by movements 
(n=3), lack of adherence to task instructions (n=2) or early break off during scanning 
(anxiety, n=5), which resulted in a study population of 28 patients.
Controls
Healthy control subjects (n=29) were recruited from the general population through 
advertising. They were closely matched to the patient group with respect to age, 
gender and education. Both patients and controls underwent an identical neuro-
psychological examination. Seven controls were left out of the analysis because of the 
presence of silent brain infarcts (n=4) or pre-existent cognitive decline (n=3). 
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The medical ethics committee (CMO Arnhem-Nijmegen, The Netherlands) approved 
the study protocol. All subjects gave written informed consent to participate in this 
study and only travel costs were reimbursed.
Episodic memory assessment
All patients underwent a complete, standardised neuropsychological examination 
between 6-8 weeks after their qualifying stroke covering all cognitive domains, 
including assessment of mood. Episodic memory was assessed with the California 
Verbal Learning Task, Dutch version (CVLT) [Delis 1987]. We were particularly 
interested in the delayed-recall because this measure is most sensitive to MTL function 
[Hermann et al. 1987;Mungas et al. 1985]). Other relevant tests for the purpose of this 
particular study included; global cognition (MMSE), pre-existent cognitive decline 
(IQCODE), and anxiety and depressive symptoms (Hospital Anxiety Depression Scale 
(HADS) [Zigmond and Snaith 1983]). In addition, educational level was assessed in 
all subjects using the Dutch classification system [Verhage 1964], ranging in ascending 
order from 0 (less than primary school) to 7 (university degree).
Other covariates
Clinical stroke severity at admission was assessed with the National Institute of Health 
Stroke Scale (NIHSS)[Brott et al. 1989]. Infarcts were classified according to location 
by an experienced stroke neurologist (FEdL) according to a standard procedure using 
neuroimaging (either CT or MRI) at which the symptomatic lesion was best visible. We 
also assessed the post-stroke functional status 6-8 weeks after stroke by the Barthel 
Index (BI) [Mahoney and Barthel 1965];[Mahoney and Barthel 1965] ranging from 0 
(completely dependent) to 20 (completely independent), and degree of handicap 
(modified Rankin Scale (mRS) [van Swieten et al. 1988]; ranging from 0 (no symptoms) 
to 5 (severe disability). 
fMRI Task design
Patients were scanned 9-12 weeks after the stroke. As fMRI task design we used a 
number variant version of the n-back working memory paradigm [Gevins and Cuttilo, 
1993]. The n-back task is a paradigm which activates a so-called working memory 
(WM) network that consists of bilateral prefrontal cortex, parietal cortex, anterior 
cingulate, and bilateral cerebellum [Callicott et al. 1999;Callicott et al. 2000], whereas 
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MTL deactivation is also observed [Callicott et al. 2000;Meyer-Lindenberg et al. 2001]. 
In this study an n-back task was used with a sequence of 0-back (minimal WM load) 
and 2-back conditions (moderate WM load) arranged in a blocked design.
In the scanner, subjects viewed single digits (digits 1-9) in white arial font on a black 
background on a screen in pseudo-random order. Each digit appeared 0.6 s, after 
which the subjects had to react within 1.5 s by pressing the response button for the 
target digit. The two conditions (0-back and 2-back) were applied in alternating blocks 
of 15 digits. The whole experiment consisted of 10 cycles and thus each subject had 
to respond to 300 digits. The task took about 12 minutes and 19 seconds, in which 
308 whole brain images were recorded. In the 0-back task subjects had to respond to 
target digit ‘1’. The 2-back task required the subject to press the response button 
when a digit occurred which matched the one presented two digits before. Both 
conditions contained 15% target digits. Subjects were instructed in detail with task 
examples on a computer outside the scanner until they understood the task procedure. 
During the experiment subjects were reminded of the actual condition by continuous 
presentation of the following symbols on the screen: ‘−‘ indicated the 0-back condition 
and ‘‘ indicated the 2-back condition. 
Data acquisition
MR data were acquired with a 1.5T Siemens (Erlangen, Germany) Sonata MR scanner, 
equipped with a circularly polarised head coil. One run of T2*-weighted blood 
oxygenation level-dependent (BOLD) images was acquired using echo-planar 
imaging (EPI) with each image volume consisting of 35 axial slices [voxelsize 3 mm x 
3.5mm x 3.5mm; repetition time (TR), 2.40 s; echo time (TE), 30 ms; 64x64 matrix; field 
of view (FOV), 224 mm x 224; flip angle, 90°]. After the functional run, a high-resolution 
T1-weighted structural MR image was acquired for coregistration and spatial 
normalisation procedures [3D MP-RAGE (magnetisation-prepared rapid 
gradient-echo); TR, 2.25 s; TE, 3.68 ms; 176 contiguous 1mm slices; 256x256 matrix; 
FOV, 256 mm]. 
Total brain volume was calculated as the sum of the volumes of grey matter (G) and 
white matter (W) which were assessed by automated segmentation of high-resolution 
T1-weighted structural MR images using SPM5 (http://www.fil.ion.ucl.ac.uk/spm/). All segmented 
volumes were visually checked using MRIcron (http://www.sph.sc.edu/comd/rorden/mricron/) . 
Hippocampal volume was assessed by manual segmentation using the interactive 
software program ‘ITK-SNAP’ (http://www.itksnap.org) according to a standardised protocol 
[Brierley et al. 2002;Geuze et al. 2005] with a high interrater agreement (intraclass 
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correlation coefficient for the left and right hippocampus of 97% and 96%, respectively). 
Hippocampal volumes were adjusted for total brain volume. This segmentation was 
done without prior knowledge of both performances on memory tasks and degree of 
MTL activation during the fMRI experiment.
Data analysis 
The first three EPI volumes were discarded to allow for T1 equilibration. Data were 
analysed in MATLAB 7.1 (http://www.mathworks.com ) using the statistical parametric mapping 
software SPM5 with the following preprocessing steps: spatial realigning to correct 
subject motion (none of the subjects exceeded 3 mm motion), coregistration to the 
mean of functional images using mutual information optimisation, slice time correction, 
spatial normalisation to the Montreal Neurological Institute (MNI) T1 template, and 
spatial smoothing with a Gaussian kernel of 8 mm full-width at half-maximum. 
A general linear model [Friston et al. 1995] was used to analyse the data. Regressors 
for the 0-back and 2-back task were convolved with the canonical hemodynamic 
response function (HRF). To adjust for movement-related activation, the realignment 
parameters were also added to the model as regressors. The data were high pass-filtered 
(128 s) to account for low-frequency effects. Contrast images were created for each 
subject summarising the differences between conditions (0-back minus 2-back, and 
2-back minus 0-back contrast). The single-subject contrast images were entered into 
second-level random-effects analysis. Group level SPM(t) maps were thresholded at 
p=0.001 (uncorrected) and the cluster-size statistics FWE (Familywise Error) corrected 
were used as the test statistics. Only clusters at p(FWE)≤ 0.05 were considered 
significant. As we had an a priori hypothesis about the MTL (reduced MTL functionality 
is linked to impaired episodic memory function after stroke), a small volume correction 
was used for the MTL [Worsley et al. 1996]. For this purpose the MTL region of interest 
from the SPM anatomy toolbox (version 1.5 S. Eickhoff, institute for Medicin, research 
centre Jülich) was used. A two-sample t-test was applied to investigate the differences 
in brain activity between patients and control group during the 0-back minus 2-back 
contrast and 2-back minus 0-back contrast. 
Baseline and clinical characteristics were analysed using SPSS version 14.0. 
Two-sample t-tests were used for between group comparison for continuous data, 
Chi Square tests for nominal data and Mann Whitney U analyses were used for 
non-parametric data. All effects were tested at the p<0.05 level (two-tailed). 
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Results
Subjects’ characteristics
The study population consisted of 50 subjects with a mean age of 54.2 years (SD12.8), 
46% of them were female, median educational level was 5 and 84% was right handed. 
Baseline characteristics of both patients and controls are presented in table 1. No 
significant differences were found for age, gender, education and handedness between 
patients and controls. Total brain volume, grey matter volume, white matter volume, and 
hippocampal volume did not significantly differ between patients and controls. 
Clinical and behavioural characteristics of patients and controls are presented in table 2. 
There were no differences between patients with a left or right sided stroke. There 
were nine patients who had an infarction in the internal capsule (six left; three right), 
five in the corona radiata (four right; one left), three in the thalamus (one right; two left), 
four in the occipital lobe (two right; two left), four in the brain stem and three in the 
parietal lobe (two right; one left). 
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Table 1 Baseline characteristics 
patients
(n=28)
controls
(n=22)
Age in years (SD) † 53.7(12.6) 51.5(12.9)
Male % $ 57.1 50.0
Education (range) # 5(0-7) 5(2-7)
Right handed % $ 85.7 81.8
Left sided infarction % 46.4
Total brain volume (SD) † 1159(129.3)* 1143(122.9)**
Grey matter volume (SD) †† 661(67.9)* 659(77.1)**
White matter volume (SD) †† 498(68.6)* 484(58.5)**
Hippocampal volume (SD) †† 7.1(1.0) 6.7(0.9)
Values represent means (SD), median (range), proportions (%) or ml (volume), empty cells 
Indicates no assessment, * data available for n=27, ** data available for n=21, † Univariate 
Analysis, † †corrected for total brain volume, $ Chi Square Analysis, # Mann Whitney U
analysis; score 5 means 10-11 years of education. No significant differences were found 
between patients and controls for all these baseline characteristics (p<0.05). 
89
Patients performed significantly worse (mean words 9.2(SD 4.6)) than controls (mean 
words 12.4 (SD 2.0)) on the delayed recall task of the CVLT (p= 0.004). There was no 
difference between other clinical and behavioural characteristics, except for the 
MMSE score. Despite the difference in episodic memory function, patients and 
controls did not perform significantly different on the n-back task in the scanner. 
fMRI responses
Patients and controls
In the 0-back minus 2-back contrast brain activation was observed bilaterally in the 
frontal lobe, medial temporal lobe, cingulate gyrus, insula, occipital lobe and cerebellum 
(figure 1A). In the 2-back minus 0-back contrast brain activation was observed bilaterally 
in the frontal lobe, brain stem (pons), cerebellum and temporal lobe (figure 1B). These 
two activation patterns (figure 1A,B) correspond with brain areas typically activated by 
the n-back paradigm [Callicott et al. 1999;Callicott et al. 2000;Meyer-Lindenberg et al. 
2001]. These activation patterns were similar for patients and controls. 
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Table 2 Clinical and behavioural characteristics of participants 
Patients
n=28
Controls
n=22
MMSE (SD) † 28.1(1.7)* 29.4(0.8)#
Delayed recall words (SD) † 9.2(4.6) 12.4(2.0)#
HADS anxiety (range) † 5.5(0-12)** 4.5(0-14)
HADS depressive symptoms (range) † 4.0(0-17)** 2.5(0-14)
Modified BI (SD) 20(0.0)** 20(0.0)
Modified Rankin scale (range) 1(0-3)**
NIHSS score (range) 2(0-16)***
Correct responses on n-back task (%)
0-back condition mean (SD) † 99.1(2.3) 99.7(0.7)
2-back condition mean (SD) † 93.3(4.7) 94.9(2.8)
Values represent means (SD), median (range) or proportions (%), empty cells indicates no
assessment, * data available for n=27, ** data available for n=26, *** data available for
n=25,  † Univariate Analysis, # Significant differences between patients and controls (p<0.05)  
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Furthermore, we found a positive correlation between MTL activation (in the 0-back 
minus 2-back contrast) and CVLT performances in controls (ß=0.48, p=0.02), that 
was significantly different from patients.
Patients versus Controls
Exploratory whole brain analysis revealed no significant differences (p(FEW) >0.05) 
between stroke patients and controls, probably due to limited power as the study was 
designed to look exclusively at MTL functionality in a heterogenous group of stroke 
patients.
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Figure 1  Whole brain activation pattern of 22 controls during (A) 0-back minus 
2-back contrast and (B) 2-back minus 0-back contrast, thresholded at 
P=0.001 uncorrected
(A)
(B)
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As we wanted to compare MTL functionality (assessed with the n-back task) between 
patients and healthy controls, we subsequently focused specifically on the MTL. Both 
patients and controls showed MTL activation during the 0-back minus 2-back contrast, 
however patients showed significantly less left sided MTL activation (x = -18, y = -32, 
z = -10, t = 4.42, k = 27, p(FWE) = 0.02) than healthy matched controls (figure 2). 
Additionally, there was a trend for the right sided MTL activation (x = 32, y = -38, z = 
-10, t = 3.70, k = 13, p(FWE) = 0.12). No significant differences were observed in the 
opposite contrast (2 minus 0 back). 
Discussion
To our knowledge, this is the first study that investigates medial temporal lobe function 
and episodic memory performance among stroke patients. We found reduced MTL 
activation assessed by an n-back paradigm in stroke patients. In addition, stroke patients 
had a reduced episodic memory function compared to healthy matched controls. 
A strong element in our study is the large sample size (28 stroke patients), in contrast 
with many other fMRI studies that often investigated less than 20 patients [ Meyer-
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Figure 2  Difference in MTL activation between healthy controls (n=22)  
and stroke patients (n=28) during 0-back minus 2-back contrast. 
Healthy controls showed significantly more MTL activation than 
patients during the 0-back minus 2-back contrast, thresholded at 
P=0.001 uncorrected
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Lindenberg et al. 2001;Harvey et al. 2005;Meisenzahl et al. 2006] leading to the 
possibility of finding false negative results (type II error). Another strong element is our 
high response of 73%, which may imply a high external validity. Furthermore, episodic 
memory was assessed blinded to MTL function. Another important issue is the 
 generalisability of our study, because we included all stroke patients regardless of the 
size and side of the infarction. This was done intentionally because a recent systematic 
review [Snaphaan and de Leeuw, 2007] found no evidence between lesion location 
and memory dysfunction. Therefore, our findings may be generalized towards any 
first-ever stroke patient with an acute symptomatic supratentorial cerebral infarction. 
However, there are also some methodological aspects that need to be considered. 
We used the activations in the MTLs in a working memory task to assess the 
‘functionality’ of the MTLs in an episodic memory task. This is in line with previous 
research that used a similar approach [Johnson et al, 2001; Egan et al, 2003]. 
In accordance with these studies we also found a positive correlation between MTL 
activation in the 0-back minus 2-back contrast and CVLT performances in controls 
(ß=0.48, p=0.02), that, differed significantly from the stroke patients. This finding 
suggests that reduced MTL functionality may be responsible for the impaired 
post-stroke episodic memory function. Furthermore, one could question the validity 
of functional MRI in patients with a compromised cerebrovascular circulation. fMRI 
relies on the Blood Oxygen Level Dependent (BOLD) signal that is presumably 
dependent on intact cerebrovascular responses. However, the fact that we were able 
to detect fMRI responses as predicted from previous studies that used the n-back 
task [Callicott et al. 1999;Callicott et al. 2000;Meyer-Lindenberg et al. 2001] makes 
this unlikely. In addition, recent methodological studies on the validity of fMRI in stroke 
patients confirmed its usefulness [Kimberley et al. 2007]. 
Critics could argue that reduced MTL activation is simply a consequence of impaired 
performance on the n-back task by the stroke patients. However, despite the fact that 
patients performed worse on the delayed recall task, they did not on the n-back task; 
making this explanation rather unlikely. Another explanation for our finding of a 
reduced MTL activation among stroke patients could be differential selection of 
patients with already pre-existing cognitive decline. However, this seems unlikely as 
we only included patients that showed no signs of prestroke cognitive decline, as 
assessed with the IQCODE. Furthermore, memory function is known to be affected by 
many environmental factors and structural brain correlates including depressive 
symptoms, anxiety, total brain volume and hippocampal volume [Kauhanen et al. 
1999;Kizilbash et al. 2002;Sullivan et al. 1996;Lupien et al. 1998]. As patients were 
carefully matched with controls with respect to these factors, we consider it unlikely 
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that this differential MTL activation is explained by other group differences, except for 
the stroke. 
Another explanation for a reduced MTL functionality could be a systemic reaction as 
a response on a cerebral event. Support from this notion comes from a study that 
found increased glucocorticoids levels in acute stroke patients compared with controls 
[Szczudlik et al. 2004]. Subsequently, several studies have demonstrated that elevated 
glucocorticoids levels results in a reduction of hippocampal volume and deficits in 
hippocampus dependent memory tasks compared to normal glucocorticoids controls 
[Elgh et al. 2006;Lupien et al. 1998;de Quervain et al. 2003]. However, we consider 
this explanation unlikely as both episodic memory assessment and the fMRI 
experiments were performed about 2-3 months after the qualifying stroke. Longitudinal 
studies on the time course of glucocorticoids levels after stroke have shown 
normalization within weeks after the stroke [Cohan et al. 2005;Ibrahimagic et al. 
2005;Marklund et al. 2004;O’Neill et al. 1991]. 
Emerging evidence from functional neuroimaging, neurophysiology and computational 
modeling highlights the importance of interaction between the MTL, parietal cortex, 
thalamus and prefrontal cortex for a proper episodic memory function [Simons and 
Spiers 2003]. Any lesion or disconnection in this network (due to for example an 
infarction in white matter structures that connect the MTL with the other relevant 
structures or due to underlying psychiatric disease including schizophrenia [Callicott 
et al. 2000]) may result in an accompanying memory dysfunction, possibly due to a 
lesser functionality of the MTL or of any other element of the network. Support for this 
notion comes from a diffusion tensor imaging study among patients with traumatic 
brain injury [Kraus et al. 2007]. In this study, Kraus and colleagues found that focal 
traumatic white matter abnormalities (not located in the MTL) were related with 
memory dysfunction. So, MTL functionality seems to depend on intact connections of 
the MTL with other brain regions and this functionality can be reduced due to 
disruptions of the connecting fibre tracts. Consequently, one could argue that stroke 
patients with an episodic memory function comparable with controls presumably 
would have a “normal” MTL functionality as well. Unfortunately our sample of stroke 
patients was too small to reliably compare “normal” with “impaired” episodic memory 
performers. 
Clinically, our study could contribute to the early identification of stroke patients with 
reduced episodic memory function due to impaired MTL functionality. By enlarge, 
stroke patients are at increased risk for developing post-stroke dementia [Loewenstein 
et al. 2004] (which is even three times higher than the risk of a recurrent stroke [Yokota 
et al. 2004]). To date it is not possible to identify the ones at risk, but our study may 
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provide diagnostic opportunities in this identification. Prospective studies are now 
needed to determine whether those with impaired MTL functionality are indeed at 
increased risk for post-stroke dementia. To unravel the underlying mechanisms of 
impaired MTL functionality some of these studies should investigate stroke patients 
with infarcts at similar locations with the aid of diffusion tensor imaging to study their 
effect on (loss of) connectivity within the episodic memory network.
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4.1  Prospective study about post-stroke fatigue and 
possible predictors
Abstract
Post-stroke fatigue (PSF) often occurs after stroke and has a negative impact on the 
rehabilitation process. Several studies focused either on short- or on long-term PSF 
and their direct relations with stroke characteristics. However, possible pre-stroke 
confounders like history of depression, pre-existent white matter lesions or brain 
atrophy were hardly taken into account. Therefore the precise mechanisms underlying 
PSF remain still unclear. This study was aimed to assess the possible contributions of 
(pre-) stroke factors to both short-term PSF and its subsequent course over time.
This study pertains to 108 patients with an acute cerebral infarction. PSF was rated by 
the Checklist Individual Strength at two months and 1.5 year post-stroke. The relation 
between (pre-)stroke factors and PSF was assessed with multivariate regression 
analysis. 
The prevalence of baseline PSF was 35% and at follow-up 33%. Older age had a 
protective effect on PSF at baseline (OR 0.95; 95% CI 0.91-0.98), whereas depressive 
symptoms and infratentorial infarctions were an increased risk for PSF (OR 1.40; 95% 
CI 1.21-1.63 and OR 4.69; 95% CI 1.03-21.47, respectively). Baseline fatigue was 
related to an increased risk of PSF at follow-up (OR 1.15; 95% CI 1.09-1.22). Depressive 
symptoms and baseline fatigue were associated with PSF deterioration over time (OR 
1.32; 95% CI 1.04-1.67 and OR 1.11; 95% CI 1.00-1.24, respectively).
Predictors for PSF were younger age, depressive symptoms and infratentorial 
infarctions. Baseline fatigue did predict fatigue outcome over time, suggesting that 
early interventions might be useful to prevent deteriorated PSF. 
Liselore Snaphaan, Sieberen van der Werf, and Frank-Erik de Leeuw. Time course and risk 
factors of post-stroke fatigue:A prospective cohort study. submitted.
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Introduction
The prevalence of post-stroke fatigue (PSF) varies between 39% and 72% and it is 
one of the greatest barriers to rehabilitation and has a negative impact on post-stroke 
quality of life [1-3]. Fatigue has a high prevalence in many neurological disorders with 
predominantly focal cerebral lesions (multiple sclerosis [4]) as well as in disorders 
with a more diffuse cerebral pathology (Parkinson disease [5]), but also in disorders 
with primarily neuromuscular involvement (muscular dystrophy [6]). This suggests 
that fatigue encompasses the clinical spectrum of many neurological disorders and is 
not so much due to a lesion in a certain brain area rather than any disease affecting 
both the central and peripheral nervous system and the attendant limitations in daily 
living. This corresponds with studies that suggested post-stroke fatigue (PSF) to be 
secondary to post-stroke functional impairment, psychological distress or recovery 
process [7, 8]. 
The prevalence of (PSF) is high, but reportedly highly variable [9] due to methodological 
differences between studies including patient inclusion, assessment of fatigue, 
assessment at different time-points after the stroke, and in the collection of (post-) 
stroke characteristics.
The post-stroke course of fatigue is virtually unknown. From a clinical perspective 
knowledge on risk factors for PSF, and more particularly, for persistent PSF may lead 
to early identification of those at risk for persistent PSF. This recognition is important 
as nowadays there is ample proof of effective treatment strategies for PSF [10].
From the etiologic perspective the relation between stroke and the occurrence of 
fatigue may be obscured by possible confounders, like type of stroke, location of 
lesion and physical disability. Although some studies [1, 7, 11] took these possible 
confounders into account, there are no studies taking pre-stroke confounders (factors 
that were presumably already be present before the stroke) into account, like 
depression [12], vascular white matter lesions (WML) [13], cerebral atrophy [14]. For 
example, since white matter lesions are more prevalent among stroke patients [15] 
they may, at least in part, explain the increased prevalence of fatigue symptoms. 
The aim of the present study was to investigate the prevalence, course and possible 
risk factors of PSF. In addition, we wanted to estimate the risk of baseline and long-term 
course of PSF, adjusted for stroke and pre-stroke related factors by the use of 
multivariate models.
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Methods
Study population
All patients that presented with acute symptomatic ischemic infarction according to 
the WHO diagnostic criteria [16] who were admitted to the Neurology department of 
the Radboud University Nijmegen Medical Centre, the Netherlands were eligible for 
enrolment in the prospective Nijmegen Stroke Study. The Nijmegen Stroke Study 
prospectively investigates short- and long-term consequences of stroke with regular 
preplanned assessments after stroke. 
Inclusion criteria for enrolment in this study were: acute ischemic infarction and fatigue 
assessment at 6-8 weeks post-stroke and 1.5 year post-stroke. Therefore, the final 
study population included 108 patients who were screened for PSF at two time point 
after the stroke (figure 1). The local medical ethics committee of the Arnhem Nijmegen 
region approved the study.
The diagnosis of ischemic infarction was based on the presence of acute neurological 
symptoms that could only be explained by a vascular event in a specific arterial 
territory with a duration of > 24 hrs and verified by CT or MRI. Ischemic infarction was 
further classified as first-ever (i.e. occurring in patients either without previous clinical 
stroke according to a structured questionnaire nor without ischemic lesions other than 
the corresponding lesion of the acute clinical stroke on CT/MRI) and ever stroke 
(defined as patients with a history of previous stroke according to a structured 
questionnaire with or without corresponding ischemic lesions on CT/MRI). 
Assessment of PSF
The presence of fatigue was rated by self-assessment of the Checklist Individual 
Strength (CIS [17] at two time points after the stroke (i.e at 6-8 weeks post-stroke 
(baseline) and 1.5 year post-stroke (follow-up)). This screening instrument is 
well-validated in studies among stroke patients [1, 8]. The fatigue subscale indicates 
the level of experienced fatigue over the past 2-week period and contains 8 fatigue 
items that have to be answered on a 7-point scale. The score can range from 8 (no 
fatigue) to 56 (severe fatigue). A score above 35 is considered indicative for severe 
fatigue [17] and has been found to correlate highly with a formal diagnosis of a fatigue 
based on DSM-IV criteria. 
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Course of PSF 
The course of PSF was classified as follows: no PSF (patients without fatigue (CIS 
fatigue ≤ 35) at baseline and follow-up); persistent PSF (patients with severe fatigue 
(CIS fatigue>35) both at baseline and follow-up); recovered from PSF (patients with 
fatigue at baseline and without fatigue at follow-up) and incident PSF (patients without 
fatigue at baseline but with fatigue at follow-up). 
Assessment of possible pre-stroke confounders
 
Standard questionnaires were used to obtain information about age, gender, martial 
status, educational level (i.e Dutch classification system [18], ranging in ascending 
order from 1 (less than primary school) to 7 (university degree)) and pre-stroke 
depression (defined as “history of depressive symptoms” as depressive episodes 
that had required attention of a general practitioner, psychologist, or psychiatrist) [19].
White matter lesions (WML) were rated at admission according to the Age Related 
White Matter Changes-scale [20]. Subcortical atrophy was defined as the mean ven-
tricle-to-brain ratio at the frontal, bicaudate and occipital level [21]. Cortical atrophy 
was defined as the mean width of the left and right Sylvian fissure divided by the 
maximum brain width (at the pineal level [21]), or in absence of either of these (in 1% 
of all cases), the width of one Sylvian fissure divided by the maximum brain width, 
multiplied with two, was used. Subcortical atrophy was defined as the mean ventricle-
to-brain ratio at the frontal, bicaudate and occipital level [21], the three ventricle-to-
brain ratio were available in all cases.
Assessment of possible stroke-related confounders
 
The side of a stroke was judged on the basis of the acute clinical neurological 
symptoms at admission (classified as left or right hemispheric stroke or infratentorial 
stroke (i.e cerebellum or brainstem). Stroke severity was assessed at baseline with the 
National Institute of Health Stroke Scale (NIHSS) [22]. Cortical lesions (ie frontal, 
parietal, temporal, occipital lobes), subcortical lesions (white matter, basal ganglia, 
thalamus), both cortical and subcortical, and infratentorial lesions were identified and 
rated by an experienced stroke neurologist (FEdL), according to a standard procedure 
using neuroimaging (either CT or MRI) at which symptomatic lesions were best 
visible. 
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Global cognition (MMSE), functional status (Barthel Index (BI) [23][Mahoney and 
Barthel 1965] ranging from 0 (completely dependent) to 20 (completely independent)) 
and the degree of handicap (modified Rankin Scale (mRS) [24] ranging from 0 (no 
symptoms) to 5 (severe disability)) were assessed at baseline. Patients with a mRS 0-1 
were classified as 'favourable', those with with a mRS ≥2 were classified as 
'unfavourable'.
Statistical Analysis
Two-sample t-tests were used for group comparison of continuous data, Chi Square 
and Mann Whitney U testing were used for nominal and for non-parametric data, 
respectively. To investigate significant differences within the four groups, univariate 
analysis with post-hoc Scheffé corrections were used. All tests were two-tailed with 
the results considered significant at p<0.05. 
The relations between the risk of PSF (defined as a fatigue score > 35 on CIS) and the 
several pre- and post-stroke risk factors were assessed with age and sex adjusted logistic 
regression analyses. Subsequently, the predictor variables that turned out to be 
significantly related in the age and sex adjusted logistic model were then introduced into 
a step-backward logistic regression (conditional) analysis to calculate independent risk 
factors for PSF, presented as odds ratios (OR), with 95% confidence interval (95% CI). 
Results
The final study population consisted of 108 stroke patients with a mean age of 65.0 
years (SD12.9) at baseline, 36% of them were female, median educational level was 5 
(high school level) and 24 % were living alone, the mean fatigue (CIS) score at baseline 
was 30.3 (SD 14.6) and at follow-up 29.5 (SD 13.9, data not shown). 
Prevalence of PSF at baseline and follow-up
The prevalence of PSF was 35% within 2 months after stroke and 33% at 1.5 year 
post-stroke (follow-up). Younger age (p<0.01), higher score of post-stroke anxiety 
(p<0.01) and depressive symptoms (p<0.01) were significantly related with PSF at 
baseline (adjusted for age and gender), as was a higher degree of post-stroke 
handicap (mRS p=0.03). There were no significant differences between patients with 
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PSF and patients without PSF for pre-stroke characteristics at baseline (table 1). 
In addition, younger age (p<0.01), higher score of anxiety (p=0.03) and depressive 
symptoms (p<0.01) assessed at baseline were also significantly related with PSF at 
follow-up (adjusted for age and gender, table 1), whereas there was no relation 
between higher degree of handicap and PSF at follow-up (p=0.14). 
Course of PSF
 
In total 108 stroke patients were followed with a mean follow-up of 1.5 year, 57% of the 
patients did not have PSF at all, whereas 26% of the patients had PSF at both time 
points. Nine percent of the patients had fatigue at baseline but recovered at follow-up 
and 8% of the patients had no PSF at baseline but they did at follow-up. In univariate 
analysis, patients without fatigue at both time points were significantly older compared 
to those who developed PSF (p=0.02) and also had lower score of depressive 
symptoms (p=0.01) compared to those with PSF at both post-stroke time points or to 
those who recovered from PSF (table 2). 
Stroke related risk factors of PSF at baseline or follow-up
 
In age and gender adjusted logistic regression analysis (table 3), the presence of an 
infratentorial infarct was a risk factor for PSF at baseline (OR 4.10; 95% CI 1.04-16.12) 
compared with those with an infarction at another location. In addition, post-stroke 
anxiety and/or depressive symptoms were significantly associated with an increased 
risk of PSF at baseline (OR 1.18; 95% CI 1.03-1.35 per each point increase on the 
HADS anxiety items, OR 1.36; 95% CI 1.17-1.57 per each point increase on the HADS 
depressive symptoms items, respectively). Whereas older age had a protective effect 
on PSF at baseline and follow-up (OR 0.94; 95% CI 0.91-0.98 and OR 0.95; 95% CI 
0.92-0.98 per increase of age, respectively). Risk factors for PSF at follow-up were 
those with a higher fatigue level at baseline (OR 1.15; 95% CI 1.09-1.21 per each point 
increase on the CIS fatigue items)  as had patients with anxiety or depressive 
symptoms, OR 1.15; 95% CI 1.01-1.31 per each point increase on the HADS anxiety 
items, OR 1.30; 95% CI 1.14-1.49 per each point increase on the HADS depressive 
symptoms items, respectively). In an age and sex adjusted regression analysis, 
patients with an infratentorial infarction were not at risk for PSF at follow-up (OR 1.78; 
CI 0.48-6.56) compared with those with an infarction at another location.
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Table 1  Demographics and patients’ characteristics classified by presence or  
absence of post-stroke fatigue at baseline or follow-up 
Fatigue at baseline Fatigue at follow-up
Demographics Absent 
N=70 
Present
N=38 
P-value Absent 
N=72
Present
N=36
P-value
Age mean (SD) * 68.2(12.1) 59.0(12.3) <0.01 67.8(11.8) 59.3(13.3) <0.01
Female gender (%)† 30 47 0.07 32 44 0.22
Living alone (%)† 28 18 0.37 23 28 0.55
Education median (range) ‡ 5(1-7) 5(1-7) 0.87 5(1-7) 5(1-7) 0.29
Post-stroke characteristics
Behavioural characteristics
MMSE mean (SD) * 27.1(2.7) 27.6(2.7) 0.37 27.3(2.6) 27.3(2.9) 0.33
Anxiety mean (SD) * 3.8(3.2) 6.4(4.0) <0.01 3.9(3.1) 6.3(4.3) 0.03
Depressive symptoms mean (SD) * 2.7(2.8) 7.1(4.6) <0.01 2.9(2.8) 7.0(4.9) <0.01
Clinical characteristics
Barthel index median (range) * 20(10-20) 20(9-20) 0.38 20(10-20) 20(9-20) 0.81
Modified Rankin Scale median (range) ‡ 0(0-3) 1(0-3) 0.03 0(0-3) 1(0-3) 0.14
NIHSS median (range) * 0(0-5) 1(0-8) 0.09 0(0-8) 0(0-5) 0.55
First-ever stroke (%)† 71 76 0.58 74 72 0.88
Left hemisphere/Right hemisphere (%)† 47/47 46/35 0.54 49/43 43/43 0.78
Infratentorial (%)† 6 19 0.03 8 14 0.34
Imaging characteristics
Lesion location cortical/subcortical/both (%)† 13/79/8 33/44/23 0.07 16/72/12 29/53/18 0.44
Subcortical structures:
White matter/Basal ganglia/Thalamus (%) 74/16/10 75/0/25 0.36 72/17/11 78/0/22 0.36
Pre-stroke characteristics
History depressive symptoms (%)† 6 8 0.65 6 8 0.61
ARWMC median (range) * 0(0-29) 0(0-4) 0.10 0(0-29) 0(0-5) 0.17
Values represent means (SD), median (range) or proportions (%), P-values were calculated between 
presence and absence of fatigue at baseline adjusted for age (for continues data), significant values  
(p < 0.05) are printed bold, * Univariate t-test (continue data), † Chi-square analyses (categorical data), 
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Table 1  Demographics and patients’ characteristics classified by presence or  
absence of post-stroke fatigue at baseline or follow-up 
Fatigue at baseline Fatigue at follow-up
Demographics Absent 
N=70 
Present
N=38 
P-value Absent 
N=72
Present
N=36
P-value
Age mean (SD) * 68.2(12.1) 59.0(12.3) <0.01 67.8(11.8) 59.3(13.3) <0.01
Female gender (%)† 30 47 0.07 32 44 0.22
Living alone (%)† 28 18 0.37 23 28 0.55
Education median (range) ‡ 5(1-7) 5(1-7) 0.87 5(1-7) 5(1-7) 0.29
Post-stroke characteristics
Behavioural characteristics
MMSE mean (SD) * 27.1(2.7) 27.6(2.7) 0.37 27.3(2.6) 27.3(2.9) 0.33
Anxiety mean (SD) * 3.8(3.2) 6.4(4.0) <0.01 3.9(3.1) 6.3(4.3) 0.03
Depressive symptoms mean (SD) * 2.7(2.8) 7.1(4.6) <0.01 2.9(2.8) 7.0(4.9) <0.01
Clinical characteristics
Barthel index median (range) * 20(10-20) 20(9-20) 0.38 20(10-20) 20(9-20) 0.81
Modified Rankin Scale median (range) ‡ 0(0-3) 1(0-3) 0.03 0(0-3) 1(0-3) 0.14
NIHSS median (range) * 0(0-5) 1(0-8) 0.09 0(0-8) 0(0-5) 0.55
First-ever stroke (%)† 71 76 0.58 74 72 0.88
Left hemisphere/Right hemisphere (%)† 47/47 46/35 0.54 49/43 43/43 0.78
Infratentorial (%)† 6 19 0.03 8 14 0.34
Imaging characteristics
Lesion location cortical/subcortical/both (%)† 13/79/8 33/44/23 0.07 16/72/12 29/53/18 0.44
Subcortical structures:
White matter/Basal ganglia/Thalamus (%) 74/16/10 75/0/25 0.36 72/17/11 78/0/22 0.36
Pre-stroke characteristics
History depressive symptoms (%)† 6 8 0.65 6 8 0.61
ARWMC median (range) * 0(0-29) 0(0-4) 0.10 0(0-29) 0(0-5) 0.17
‡ Mann-Whitney U Test (ordinal data), # mean of ventricle to brain ratio at the frontal, bicaudate or 
occipital level, ** mean width of the left and right sylvian fissure divided by the maximum brain width  
(at the pineal level).
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Table 2  Demographics, stroke and behavioural characteristics at post-stroke  
fatigue patients during 1.5 year
Demographics
No fatigue*
N=62
Persistent fatigue*
N=28
Incident fatigue*
N=8
Recovery fatigue*
N=10
P-value
Age mean (SD) 68.5(11.9) 57.4(12.6) 65.8(14.2) 63.3(10.7) 0.02†
Female gender (%) 71 46 38 50 0.32
Living alone (%) 23 18 63 20 0.07
Education median (range) 5(1-7) 5(1-7) 5(2-6) 1(0-1) 0.62
Post-stroke characteristics
Baseline behavioural characteristics
Fatigue items CIS mean (SD) 20.7(8.9) 48.0(6.9) 27.8(7.3) 42.5(4.7) <0.01‡
MMSE mean (SD) 27.2(2.7) 27.4(3.0) 26.8(2.6) 28.2(1.8) 0.67
Anxiety items mean (SD) 3.5(3.0) 6.5(4.3) 5.6(4.6) 6.1(3.0) 0.02†
Depressive symptoms items mean (SD) 2.5(2.6) 7.6(5.2) 5.0(3.1) 5.9(2.4) <0.01II
Baseline clinical characteristics
Barthel index median (range) 20(10-20) 20(9-20) 20(20-20) 20(10-20) 0.73
Modified Rankin Scale median (range) 0(0-3) 1(0-3) 1(0-2) 1(0-3) 0.15
NIHSS median (range) 0(0-5) 1(0-5) 0(0-1) 1(0-8) 0.22
First-ever stroke (%) 73 75 63 80 0.86
Lesion side left/right (%) 47/47/6 41/41/19 50/50/0 60/20/20 0.61
Infratentorial lesions (%) 6 19 0 20 0.18
Pre-stroke characteristics
History depressive symptoms (%) 5 7 13 11 0.79
Subcortical atrophy ratio mean (SD) # 0.34(0.04) 0.33(0.04) 0.35(0.03) 0.31(0.03) 0.10
Cortical atrophy ratio mean (SD) ** 0.03(0.01) 0.03(0.01) 0.04(0.02) 0.03(0.01) 0.28
ARWMC median (range) 0(0-29) 0(0-4) 0(0-5) 0(0-2) 0.07
P-values were calculated with an univariate t-test (continue data), Pearson Chi-square analyses 
(categorical data), Kruskall-Wallis (ordinal data), significant values (p < 0.05) are printed bold, * no 
fatigue: no fatigue at baseline and follow-up, persistent fatigue: fatigue at both time-points, incident 
fatigue: fatigue at follow-up not at baseline, recovery fatigue: only fatigue at baseline not at follow-up,  
† significant differences between no fatigue versus persistent fatigue,  ‡ significant differences between 
no fatigue versus persistent fatigue, and no fatigue versus recovery from fatigue, and recovery from 
fatigue versus incident fatigue, and incident fatigue versus persistent fatigue, II significant differences 
between no fatigue versus persistent fatigue, and no fatigue versus recovery from fatigue, # mean of 
ventricle to brain ratio at the frontal, bicaudate or occipital level, ** mean width of the left and right 
sylvian fissure divided by the maximum brain width (at the pineal level).
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Table 2  Demographics, stroke and behavioural characteristics at post-stroke  
fatigue patients during 1.5 year
Demographics
No fatigue*
N=62
Persistent fatigue*
N=28
Incident fatigue*
N=8
Recovery fatigue*
N=10
P-value
Age mean (SD) 68.5(11.9) 57.4(12.6) 65.8(14.2) 63.3(10.7) 0.02†
Female gender (%) 71 46 38 50 0.32
Living alone (%) 23 18 63 20 0.07
Education median (range) 5(1-7) 5(1-7) 5(2-6) 1(0-1) 0.62
Post-stroke characteristics
Baseline behavioural characteristics
Fatigue items CIS mean (SD) 20.7(8.9) 48.0(6.9) 27.8(7.3) 42.5(4.7) <0.01‡
MMSE mean (SD) 27.2(2.7) 27.4(3.0) 26.8(2.6) 28.2(1.8) 0.67
Anxiety items mean (SD) 3.5(3.0) 6.5(4.3) 5.6(4.6) 6.1(3.0) 0.02†
Depressive symptoms items mean (SD) 2.5(2.6) 7.6(5.2) 5.0(3.1) 5.9(2.4) <0.01II
Baseline clinical characteristics
Barthel index median (range) 20(10-20) 20(9-20) 20(20-20) 20(10-20) 0.73
Modified Rankin Scale median (range) 0(0-3) 1(0-3) 1(0-2) 1(0-3) 0.15
NIHSS median (range) 0(0-5) 1(0-5) 0(0-1) 1(0-8) 0.22
First-ever stroke (%) 73 75 63 80 0.86
Lesion side left/right (%) 47/47/6 41/41/19 50/50/0 60/20/20 0.61
Infratentorial lesions (%) 6 19 0 20 0.18
Pre-stroke characteristics
History depressive symptoms (%) 5 7 13 11 0.79
Subcortical atrophy ratio mean (SD) # 0.34(0.04) 0.33(0.04) 0.35(0.03) 0.31(0.03) 0.10
Cortical atrophy ratio mean (SD) ** 0.03(0.01) 0.03(0.01) 0.04(0.02) 0.03(0.01) 0.28
ARWMC median (range) 0(0-29) 0(0-4) 0(0-5) 0(0-2) 0.07
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Stroke related risk factors for PSF course over time
Patients with incident fatigue (fatigue at follow-up, not at baseline) had higher fatigue 
score and more post-stroke depressive symptoms at baseline (OR 1.11; 95% CI 
1.00-1.24, per each point increase on the CIS fatigue items and OR 1.32; 95% CI 
1.04-1.69, per each point increase on the HADS depressive symptoms, respectively) 
compared to patients without PSF at both time-points. No significant differences 
could be found in (pre-)stroke related risk factors between patients with persistent 
fatigue compared to patients who made recovery.
Multivariate model
 
The variables that turned out to be significantly related in the logistic regression 
analysis (in bold table 3), were then introduced into an age and gender adjusted 
step-backward logistic regression model to calculate independent predictors of PSF 
at baseline and follow-up. Older age has a protective effect on PSF at baseline (OR 
0.95; 95% CI 0.91-0.98, per increase of age). Post-stroke depressive symptoms and 
infratentorial infarctions were related with an increased risk of PSF at baseline (OR 
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Table 3  Risk factors for post-stroke fatigue at baseline or follow-up  
(OR and 95% CI)
Fatigue at 
baseline
Fatigue at 
follow-up 
Demographics
Age 0.94(0.91-0.98) 0.95(0.92-0.98)
Gender (reference male) 2.20(0.92-5.30) 1.71(0.72-4.09)
Post-stroke baseline characteristics
Fatigue CIS na 1.15(1.09-1.21)
Anxiety 1.18(1.03-1.35) 1.15(1.01-1.31)
Depressive symptoms 1.36(1.17-1.57) 1.30(1.14-1.49)
Rankin Scale ≥ 2 (reference Rankin Scale <2) 1.78(0.68-4.66) 1.04(0.39-2.74)
Infratentorial lesion (clinical) 4.10(1.04-16.12) 1.78(0.48-6.56)
Values are Odds Ratios (95% Confidence Intervals) adjusted for age and gender, significant OR are 
printed bold (p < 0.05); na, not applicable because part of the baseline fatigue definition is based on 
the CIS score. 
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1.40; 95% CI 1.21-1.63 per point increase on the HADS depression items, OR 4.69; 
95% CI 1.03-21.47, respectively). Whereas higher score on baseline fatigue was related 
with an increased risk of PSF at follow-up (OR 1.15; 95% CI 1.09-1.22, per point 
increase on the CIS fatigue items). To calculate independent predictors of PSF over 
time, the significant predictors (in bold in table 4) were introduced into a step-backward 
regression analysis with never fatigue as reference category compared to incident 
fatigue (fatigue at follow-up, not at baseline). Higher fatigue score at baseline and 
post-stroke depressive symptoms assessed at baseline were related with an increased 
risk of PSF at patients with incident fatigue (OR 1.11; 95% CI 1.00-1.24, per point 
increase on the CIS fatigue items and OR 1.32; 95% CI 1.04-1.67 per point increase on 
the HADS depression items).
Discussion
This large prospective study showed that the prevalence of baseline and follow-up 
PSF did not differ significantly (p=0.82). In multivariate models, younger age, 
depressive symptoms and infratentorial infarcts were related with an increased risk of 
PSF at baseline, whereas higher fatigue score at baseline was related with an 
increased risk of PSF at follow-up. Those who develop PSF over time, had more often 
depressive symptoms and a higher fatigue score at baseline. 
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Table 4 Risk factors for post-stroke fatigue during time (OR and 95% CI)
Demographics Incident 
fatigue*
Recovery 
fatigue †
Age 0.98(0.93-1.04) 1.04(0.98-1.11)
Female gender 1.48(0.32-6.87) 1.04(0.23-4.64)
Post-stroke baseline characteristics
Fatigue CIS 1.11(1.00-1.24) 0.86(0.74-0.99)
Anxiety 1.18(0.96-1.45) 1.02(0.83-1.26)
Depressive symptoms 1.32(1.04-1.69) 0.86(0.71-1.08)
Values are Odds Ratios (95% Confidence Intervals) adjusted for age and gender, significant OR are 
printed bold (p < 0.05), never fatigue and persistent fatigue were reference variables,* reference: those 
without PSF during baseline and follow-up, † reference: those with fatigue during baseline and 
follow-up
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The prevalence of both baseline and long-term PSF seems lower than other studies 
that used the same fatigue rating scale. One could argue that patients who could not 
complete assessment of fatigue, might have had more severe neurological deficits 
and therefore suffered more often from fatigue. This could have led to an underestimation 
of PSF even as by excluding patients with an intracerebral hemorrhage that suffered 
more often from severe neurological deficits. Therefore our study does not represent 
the whole stroke population, although the majority of strokes constitutes of ischemic 
stroke. Another reason for our prevalence at the lower end of the spectrum could be 
that in contrast to our study, no study attempted to adjust for possible confounding 
factors that were already be present before the qualifying stroke like depression or 
white matter lesions, that, independent from the stroke, could also be related with 
fatigue [12, 13]. Our study explicitly controls for these pre-stroke factors and therefore 
we consider the 35% baseline prevalence of PSF as a reliable estimate. 
In favour of our study are its large sample size that gave us the opportunity to 
investigate pre- and post-stroke risk factors for PSF, independent from each other as 
well as independent from other risk factors, by introducing them into a multivariate 
analysis. Another strong element of our study is that this is a single centre study, with 
two investigators that performed a structured and standardised assessment with a 
well validated fatigue screenings instrument, which strengthens the uniformity and 
validity of our findings. 
In contrast to many other studies, our study found that patients with infratentorial 
infarctions were at risk for PSF at baseline and is consistent with a study from Staub 
and colleagues [25]. The brain stem is an important regulator in the autonomic 
nervous system and also plays a major role in sleep and consciousness as well as 
modulation of fatigue, and motivation to perform various activities. Imaging studies 
[26, 27] have shown abnormal activity in the brain stem in people with chronic fatigue 
syndrome. This may indicate that damage in this particular brain area may be 
associated with fatigue, for thusfar unknown reasons. Novel imaging techniques such 
as task related, but also resting state fMRI may be of use in the detection of what part 
of the brain (or what network) shows altered function in patients with PSF. These 
techniques could then, when established, perhaps also be of use in the early prediction 
of those with PSF and as such possibly guide early (cognitive) rehabilitation medicine.
Furthermore, higher degree of post-stroke depressives symptoms found in this study 
were related with an increased risk of PSF over time, independent from other risk 
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factors. This is an important finding because recent research showed a significantly 
improvement in fatigue by the use of cognitive behavioural therapy [10], and therefore 
could provide a positive effect on rehabilitation participation and/or post-stroke quality 
of life. To date, there is a paucity of prospective studies with a sufficient size of patients 
to allow stable multivariate predictive models of PSF over time, even as proper 
registration of pre-stroke characteristics collected from the medical history and from 
neuroimaging. Future research should overcome these limitations when investigating 
PSF from an etiological as well as for a prognostic perspective. In addition, rehabilitation 
studies should investigate whether early fatigue interventions might be useful to 
prevent deterioration of  PSF.
4
 post-stroke fatigue
114
Reference List
1.  Ingles JL, Eskes GA, Phillips SJ. 
Fatigue after stroke. Arch Phys Med 
Rehabil 1999;80:173-8.
2.  Michael K. Fatigue and stroke. Rehabil 
Nurs 2002;27:89-94.
3.  Morley W, Jackson K, Mead GE. 
Post-stroke fatigue: an important yet 
neglected symptom. Age Ageing 
2005;34:313.
4.  Lerdal A, Celius EG, Moum T. Fatigue 
and its association with sociodemo-
graphic variables among multiple 
sclerosis patients. Mult Scler 
2003;9:509-14.
5.  Friedman JH, Brown RG, Comella C, et 
al. Fatigue in Parkinson’s disease: a 
review. Mov Disord 2007;22:297-308.
6.  Kalkman JS, Schillings ML, van der Werf 
SP, et al. Experienced fatigue in fa-
cioscapulohumeral dystrophy, myotonic 
dystrophy, and HMSN-I. J Neurol 
Neurosurg Psychiatry 2005;76:1406-9.
7.  Glader EL, Stegmayr B, Asplund K. 
Poststroke fatigue: a 2-year follow-up 
study of stroke patients in Sweden. 
Stroke 2002;33:1327-33.
8.  van der Werf SP, van den Broek HL, 
Anten HW, et al. Experience of severe 
fatigue long after stroke and its relation 
to depressive symptoms and disease 
characteristics. Eur Neurol 
2001;45:28-33.
9.  Colle F, Bonan I, Gellez Leman MC, et 
al. Fatigue after stroke. Ann Readapt 
Med Phys 2006;49:272-4.
10.  Prins JB, Bleijenberg G, Bazelmans E, et 
al. Cognitive behaviour therapy for 
chronic fatigue syndrome: a multicentre 
randomised controlled trial. Lancet 
2001;357:841-7.
11.  Schepers VP, Visser-Meily AM, Ketelaar 
M, et al. Poststroke fatigue: course and 
its relation to personal and 
stroke-related factors. Arch Phys Med 
Rehabil 2006;87:184-8.
12.  Aaronson LS, Teel CS, Cassmeyer V, et 
al. Defining and measuring fatigue. 
Image J Nurs Sch 1999;31:45-50.
13.  Harboe E, Greve OJ, Beyer M, et al. 
Fatigue is associated with cerebral white 
matter hyperintensities in patients with 
systemic lupus erythematosus. J Neurol 
Neurosurg Psychiatry 2008;79:199-201.
14.  de Lange FP, Kalkman JS, Bleijenberg 
G, Hagoort P, van der Meer JW, Toni I. 
Gray matter volume reduction in the 
chronic fatigue syndrome. Neuroimage 
2005;26:777-81.
15.  Longstreth WT, Jr., Manolio TA, Arnold 
A, et al. Clinical correlates of white 
matter findings on cranial magnetic 
resonance imaging of 3301 elderly 
people. The Cardiovascular Health 
Study. Stroke 1996;27:1274-82.
16.  Aho K, Harmsen P, Hatano S, et al. 
Cerebrovascular disease in the 
community: results of a WHO 
collaborative study. Bull World Health 
Organ 1980;58:113-30.
17.  Vercoulen JH, Swanink CM, Fennis JF, 
et al. Dimensional assessment of 
chronic fatigue syndrome. J Psychosom 
Res 1994;38:383-92.
18.  Verhage F. Intelligentie en leeftijd 
[Inteligence and age].Assen,Van 
Gorcum 1964. 
19.  de Groot JC, de Leeuw FE, Oudkerk M, 
et al. Cerebral white matter lesions and 
depressive symptoms in elderly adults. 
Arch Gen Psychiatry 2000;57:1071-6.
chapter 4
115
20.  Wahlund LO, Barkhof F, Fazekas F, et al. 
A new rating scale for age-related white 
matter changes applicable to MRI and 
CT. Stroke 2001;32:1318-22.
21.  Gomori JM, Steiner I, Melamed E, et al. 
The assessment of changes in brain 
volume using combined linear 
measurements. A CT-scan study. 
Neuroradiology 1984;26:21-4.
22.  Brott T, Adams HP, Jr., Olinger CP, et al. 
Measurements of acute cerebral 
infarction: a clinical examination scale. 
Stroke 1989;20:864-70.
23.  Mahoney FI., Barthel DW. Functional 
evaluation: The Barthel Index. Md State 
Med J 1965;14:61-5.
24.  van Swieten JC, Koudstaal PJ, Visser 
MC, et al. Interobserver agreement for 
the assessment of handicap in stroke 
patients. Stroke 1988;19:604-7.
25.  Staub F, Bogousslavsky J. Fatigue after 
stroke: a major but neglected issue. 
Cerebrovasc Dis 2001;12:75-81.
26.  Costa DC, Tannock C, Brostoff J. 
Brainstem perfusion is impaired in 
chronic fatigue syndrome. QJM 
1995;88:767-73.
27.  Tirelli U, Chierichetti F, Tavio M, et al. 
Brain positron emission tomography 
(PET) in chronic fatigue syndrome: 
preliminary data. Am J Med 
1998;105:54S-8S.
4
 post-stroke fatigue

5Summary and Discussion

119
This thesis investigates the epidemiology and pathophysiology of several 
behavioural consequences after stroke such as depressive symptoms, cognitive 
dysfunction and fatigue. Although it may seem that many studies did so before, 
our study is to be distinguished from previous studies because of its prospective 
nature and the fact that we were able to control for potential pre-stroke behavioural 
confounders (such as depression and cognitive decline in the medical history) 
and pre-stroke neuroimaging confounders (such as white matter lesions, previous 
brain ischemia, cerebral atrophy). This final chapter provides a summary of the 
main findings of the studies described in this thesis. In addition, the most important 
methodological considerations and recommendations for future research will be 
discussed. 
Summary of the main findings
Post-stroke depressive symptoms 
In chapter 2.1 the literature on the prevalence and risk factors of post-stroke 
depressive symptoms was systematically reviewed. The prevalence of post-stroke 
depressive symptoms varied between studies from 5% to 79% within one month 
after stroke, with a tendency to decline to 8% to 59% one year after stroke. Risk 
factors for post-stroke depressive symptoms included pre-stroke depression in 
the medical history and post-stroke physical/cognitive disability. 
In our own, cross-sectional part of the study (chapter 2.2), the prevalence of 
post-stroke depressive symptoms among 420 patients was 13% two months after 
the qualifying stroke. There was no relation between post-stroke depressive 
symptoms and pre-stroke depressive symptoms and/or neuroimaging 
characteristics (such as lesion side or location, previous stroke, white matter 
lesions). In contrast, a higher degree of post-stroke handicap and functional 
dependence were risk factors for post-stroke depression.
Post-stroke memory dysfunction
We performed a systematic review on the prevalence and risk factors of post-stroke 
memory dysfunction as described in chapter 3.1. The prevalence of post-stroke 
memory dysfunction varied between studies from 13 to 50% within one month 
post-stroke, which declined from 11 to 31% one year post-stroke. Risk factors for 
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post-stroke memory dysfunction included a larger stroke volume, medial temporal 
lobe atrophy and white matter lesions. 
A possible explanation for post-stroke memory dysfunction was provided in chapter 
3.2. We found that stroke patients with lower episodic memory performance had 
lower medial temporal lobe (MTL) activation compared to healthy controls. 
It could be that this lower MTL activation is responsible for the frequent observation 
of post-stroke memory dysfunction. In our study, this reduced MTL activation was 
seen in all stroke patients, independent of the location of the infarct, as we 
intentionally included patients with strokes at any location in order to achieve 
maximum generalisability. This differential medial temporal lobe activation between 
patients and controls was independent of structural brain changes (such as total 
brain volume, grey matter volume, white matter volume and hippocampal volume). 
Post-stroke fatigue
In chapter 4 we studied the prevalence, incidence and risk factors of post-stroke 
fatigue after two and 18 months post-stroke. The prevalence of post-stroke fatigue 
among 108 stroke patients was 35% two months after stroke and this proportion 
of patients with post-stroke fatigue remained stable even at 18 months post-stroke. 
The incidence of post-stroke fatigue was 8%, meaning that patients who suffered 
from fatigue 18 months after stroke did not report such complaints at baseline. 
Risk factors for post-stroke fatigue at two months were post-stroke depressive 
symptoms and infratentorial infarctions, whereas older age appeared protective 
for post-stroke fatigue at two and 18 months post-stroke. The presence of fatigue 
two months after stroke was a risk factor for fatigue 18 months after the stroke.
General discussion of the main findings
Whereas many studies described the prevalence and risk factors of depressive 
symptoms, memory dysfunction and fatigue after stroke, there is still an ongoing 
debate with respect to the possible causes of these post-stroke behavioural 
symptoms. Some researchers have stressed a biomedical explanation in terms of 
a direct stroke effect on these symptoms, analogous to for example a hemi-paresis 
after an infarct in the pyramidal tract [1, 2], while others view these post-stroke 
behavioural consequences secondary as a psychological reaction to a major life 
event [3-5] and loss of functional independence [6]. 
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One of the reasons for the ongoing controversy on these possible causes of 
post-stroke behavioural consequences may be the lack of its structured and 
standardised assessment (chapter 2.1 and 3.1). For example, there was a wide 
variability in assessment of behavioural deficits (and if the same questionnaire is 
used, quite often each investigator uses his/her own cut off criteria in the 
operationalisation of presence or absence of the symptoms) and varying time 
intervals between stroke and the assessment of the behavioural symptoms. 
Keeping in mind that the prevalence of most post-stroke behavioural symptoms 
does not exhibit a stable time-course, one can easily understand that a comparison 
between studies about prevalence and risk factors is at least difficult, not to say 
unreliable. A standardised assessment of post-stroke behavioural deficits at well 
defined post-stroke intervals may aid in establishing a true estimate of its prevalence 
and risk factors and a better understanding of its etiology. 
Another explanation for the ongoing controversy is a lack of standardised 
assessment of pre-stroke characteristics (such as depression in the medical 
history, cognitive decline, white matter lesions, silent brain ischemia and cerebral 
atrophy) which by themselves may be related to behavioural symptoms, independent 
from the stroke, and consequently could confound the “stroke – behavioural 
symptom” relation. 
In our study (chapter 2.2), the prevalence of post-stroke depressive symptoms was 
considerably lower than in most previous studies (see chapter 2.1). This may be 
explained by our exclusion of patients with depressive episodes within one month 
before the qualifying stroke, while none of the studies described in chapter 2.1 reported 
on baseline (pre-stroke) depressive symptoms. Therefore the post-stroke prevalence 
of depressive symptoms in those studies could simply be higher by the inclusion of 
individuals who already suffered from depressive symptoms before stroke.
To investigate whether indeed the stroke itself is responsible for the emergence 
post-stroke behavioural symptoms, complete pre-stroke information should be 
available from the medical history (presence of psychiatric/depressive disorders, 
cognitive decline, previous stroke) in combination with neuroimaging data that may 
show lesions (white matter lesions, silent brain ischemia, cerebral atrophy) that 
have also been related with these behavioural symptoms.
A way to possible disentangle the post-stroke behavioural symptoms as a secondary 
result of the stroke due to a psychological reaction of a major life event, we 
postulated to study TIA patients. These patients experience a more or less similar 
life event as patients with a cerebral infarction, but do usually not develop the 
ischemic lesion.
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We found that the prevalence of post-stroke depressive symptoms did not differ 
between TIA patients and patients with a cerebral infarction two months after 
stroke. This may suggest that the development of post-stroke depressive 
symptoms, at least in part, is a psychological reaction to this major life event 
rather than a result of permanent post-stroke consequences, such as physical 
disabilities, that influence the occurrence of post-stroke depressive symptoms 
most [7, 8]. 
As with post-stroke depressive symptoms, the cause of post-stroke memory 
dysfunction also remains unclear. In the systematic review we performed (chapter 
3.1), post-stroke memory dysfunction was related to a larger lesion volume and 
pre-stroke medial temporal lobe atrophy and white matter lesions. However, these 
65 studies differed tremendously in terms of patient inclusion (sample size, age, 
first-ever or ever stroke patients), assessment of memory function and in the 
collection of stroke and pre-stroke (imaging) characteristics. Consequently the 
results should be interpreted carefully. 
The diagnosis of post-stroke dementia (the presence of post-stroke memory 
dysfunction is a symptom needed to fulfill this clinical diagnosis) is often made 
within a few months after a stroke, apparently assuming a relatively stable course 
of the post-stroke memory function. However, in our systematic review, only five 
of the 65 studies [9-13] reported the prevalence of post-stroke memory dysfunction 
at different post-stroke intervals and showed that post-stroke memory dysfunction 
is not based on a reliable time course. This may allow for potential misclassifica-
tion of post-stroke dementia when memory function changes over time. Preferably, 
standardised re-assessment of cognitive function should be performed in each 
patient diagnosed with post-stroke dementia. 
Chapter 3.2 reports on a study investigating the underlying mechanism of 
post-stroke memory dysfunction. The medial temporal lobe (MTL) is an important 
brain area for an effective formation of episodic memory. Surprisingly, many 
stroke patients exhibit memory deficits, despite the fact that most stroke patients 
do not have an infarction in MTL. This may indicate that the MTL depends, for a 
proper memory function, on connections with other brain regions and that lesions 
(like infarcts) disconnect the MTL from the network. In our fMRI study, where we 
used a number variant version of the n-back working memory paradigm [14] as 
fMRI task design. The n-back task is a paradigm which activates a so-called 
working memory (WM) network, including the MTL. We found that post-stroke 
memory dysfunction could not be explained by a reduction of MTL volume, but by 
a reduction of MTL function. 
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Critics could argue that reduced MTL activation (assessed with the n-back task) 
by stroke patients is simply a consequence of impaired performance on this task 
rather than a result of memory dysfunction. However, despite the fact that patients 
performed worse on the memory task, they did not on the n-back task; making 
this explanation rather unlikely. Another explanation for our finding of a reduced 
MTL activation among stroke patients could be differential selection of patients, 
for example by including stroke patients with already pre-existing cognitive 
decline. Therefore, reduced MTL activation is related with cognitive decline and 
not due to the stroke. However, this seems unlikely as we only included patients 
that showed no signs of pre-stroke cognitive decline, as assessed with the 
Informant Questionnaire on cognitive decline in elderly. Furthermore, memory 
function is known to be affected by many environmental factors and structural 
brain correlates including depressive symptoms, anxiety, total brain volume and 
hippocampal volume [15-18]. As patients were carefully matched with controls 
with respect to these factors, we consider it unlikely that this differential MTL 
activation is explained by other group differences, except for the stroke. 
MTL functionality seems to depend on connections of the MTL with other brain regions 
and this functionality can be reduced due to disruptions of the connecting fibre tracts. 
In chapter 4.1, we investigated an often neglected but nevertheless disabling 
post-stroke symptom, namely post-stroke fatigue. We investigated the prevalence 
of post- stroke fatigue within two months after the stroke (baseline) and after just 
over one year (follow up). We found a lower prevalence of post-stroke fatigue than 
other studies that used the same fatigue rating scale during the same time period 
after stroke. An explanation for this could be that in contrast to our study, no study 
attempted to adjust for possible risk factors that were already present before 
qualifying stroke like depression or white matter lesions, that, independent from the 
stroke, also have found to be associated with fatigue [19, 20]. In contrast to many 
other studies, we found that patients with infratentorial infarctions were at higher 
risk for PSF at baseline compared to patients with a cerebral infarction elsewhere in 
the brain. Although there have been others that reported similar findings [2]. 
The brain stem is an important regulator in the autonomic nervous system and 
also plays a major role in sleep and consciousness and thereby, either cause or 
consequence, modulates fatigue and motivates to perform various activities. 
The brain stem consists anatomically of the medulla oblongata, the pons and 
mesencephalon and all of these structures are connected with the formatio 
reticularis, a regulatory network of the arousal system. Functional brain imaging 
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studies [21, 22] have shown abnormal activity in the brain stem in people with 
chronic fatigue syndrome. This may indicate that damage due to a infarction in 
either one of the previously mentioned structures or in the connections in between 
may be associated with fatigue.
We observed a relatively stable time-course of post-stroke fatigue until just over 
one year after the stroke. Several rehabilitation studies showed that recovery of 
function usually occurs in the first weeks to months after stroke. Therefore, our 
study does not support the notion that post-stroke fatigue is a direct result of 
functional impairment, or part of a recovery process.
Methodological considerations 
There are three types of biases that should be acknowledged in order to judge 
the methodological merits of a study, namely selection bias, information bias and 
confounding. 
Selection bias
Selection bias can occur due to selective participation of patients. For example, 
patients who were not able to complete neuropsychological testing were not 
included in the study. They presumably had a larger stroke with more severe 
neurological deficits, and most likely more often suffered from severe post-stroke 
behavioural deficits (such as depressive symptoms, memory dysfunction or 
fatigue). This selection bias could results in an underestimation of the post-stroke 
depressive symptoms prevalence. On the other hand an overestimation of this 
prevalence could have occured when only patients with a minor stroke or TIA 
were not to be included in the study since they, for example, were not willing to 
participate months after a stroke from which they already had completely 
recovered. Non-responders in our study were significantly more TIA patients than 
patients with severe deficits. The prevalence of post-stroke depressive symptoms 
could therefore be a small overestimation. Special care should be given to proper 
registration of those that were excluded from the study. 
Information bias
Information bias may occur by misclassification of the risk factor, dependent on 
the outcome. For example, we aimed to investigate the relation between pre-stroke 
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neuroimaging variables (including white matter lesion, silent brain ischemia and 
cerebral atrophy) and several behavioural consequences after stroke, but one 
has to keep in mind that neuroimaging was performed directly after the qualifying 
stroke. Therefore, one cannot fully exclude the fact that early stroke signs (for 
example the appearance of hypodense areas on a CT) may have been misclassified 
as white matter lesions. For this reason white matter lesions were not rated in 
areas in which the infarction was suspected. 
Another example of an information bias is the use of medication. It is known that 
several pharmacologic agents are associated with depressive symptoms, memory 
dysfunction or fatigue including selective antihypertensive agents, cimetidine, 
indomethacin, alcohol, barbiturates, stimulant withdrawal, corticosteroids. More 
specific, patients using antidepressants may provide lower scores on the Hospital 
Anxiety Depression Scale compared to patients that do not take antidepressants. 
Therefore, medication use could result in information bias. However, the 
prescription of these drugs were not changed before the assessment of the above 
mentioned behavioural characteristics, making this source of bias less likely. 
Confounding; A confounder is associated with both the risk factor and the 
outcome and is not an intermediate factor in the causal relation between these 
two variables. Possible confounders in our studies includes pre-stroke depression, 
white matter lesions and cerebral atrophy, as they are associated with both the 
independent variable (stroke) and the outcome variable (depressive symptoms, 
memory dysfunction, fatigue). For example, we aimed to investigate the prevalence 
and risk factors of post-stroke depressive symptoms and therefore patients with 
pre-stroke depression were excluded as they could confound this relation. 
In general, study populations need to be large in order to adjust for confounders 
in a statistical reliable way. Our study included over 400 participants and therefore 
fulfilled this “size” condition.   
Clinical relevance
We found that the incidence of post-stroke depressive symptoms among 420 
stroke patients was 13%. Depressive symptoms after stroke may have a negative 
influence on successful stroke recovery [23, 24]. Vice versa, stroke patients with 
a higher degree of post-stroke handicap and/or less functional independence 
were at increased risk for post-stroke depressive symptoms. Therefore, early 
treatment of stroke patients with post-stroke depressive symptoms could possibly 
result in a better stroke recovery. 
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A bit to our surprise was the observation of an identical prevalence of post-stroke 
depressive symptoms among TIA and ischemic stroke patients. Especially as 
these patients with no post-stroke handicap or functional dependency often go 
home with no (medical) support or follow-up appointment, mainly due to the fact 
that all “visual” complaints related to the stroke event no longer exist. More care 
should be given to these patients as these disabling complaints often go unnoticed 
while recent research suggests, that behavioural rehabilitation may have a positive 
effect on post-stroke depressive symptoms, albeit this is not investigated in TIA 
patients yet. 
Post-stroke memory dysfunction is a prerequisite for the diagnosis of post-stroke 
dementia. In common clinical practice, this diagnosis is made within three months 
after a stroke, apparently assuming a relatively stable course of the post-stroke 
memory function. We found that not all patients with memory dysfunction three 
months post-stroke still had their memory deficits one year post-stroke. 
Consequently, not all criteria for the post-stroke dementia diagnosis were fulfilled 
anymore after one year. This may indicate that post-stroke dementia may be 
reversible in a substantial proportion of stroke patients. Preferably, standardised 
re-assessment of cognitive function should be performed in each patient 
diagnosed with post-stroke dementia in order to exclude false positives, and most 
importantly not to diagnose patients with a dramatic disease, that on hindsight, 
was merely based on immediate post-stroke effects on cognitive performance. 
Till now, the underlying mechanism of post-stroke memory dysfunction was still 
unclear. In our fMRI study, we showed that loss of the MTL function plays a role in 
the development of memory dysfunction after stroke. A possible explanation for 
this could be that MTL functionality depends on intact connections of the MTL 
with other brain regions and this functionality can be reduced due to disruptions 
of the connecting fibre tracts. These new insights may be helpful in identifying 
specific locations of stroke that may particularly be associated with the 
development post-stroke dementia. 
Stroke patients with an infratentorial infarction and/or post-stroke depressive 
symptoms (two months after stroke) were at increased risk for (long-term) 
post-stroke fatigue. These patients may benefit from cognitive behavioural therapy 
[25] that focuses on the reduction of fatigue. Fatigue reduction may have a 
positive effect on rehabilitation participation and/or post-stroke quality of life 
[26-28]. 
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Bottomline is that most patients with cerebrovascular disease suffer from disabling 
post-stroke behavioural complaints that often go unnoticed, unless one is 
specifically asked for. In our view the results of this thesis plea for a standardised 
structured assessment of frequent occurring post stroke behavioural symptoms 
including mood, memory (as part of the assessment of the functionality of other 
cognitive domains) and fatigue. 
Future perspectives- methodology 
Although, our study did not found a relation between post-stroke behavioural 
consequences and pre-stroke behavioural characteristics (such as depression or 
cognitive deficits in the medical history), pre-stroke neuroimaging characteristics 
(such as white matter lesions, silent brain ischemic, cerebral atrophy), formal 
studies investigating these possible risk factors are scare. Therefore, we 
suggested future stroke studies that aim to examine the behavioural consequences 
after stroke to take account of pre-stroke characteristics and to report whether 
patients were excluded from analysis based on these pre-stroke behavioural/ 
neuroimaging characteristics. 
To gain a more detailed insight into the etiology of several post-stroke behavioural 
deficits, we suggest future stroke studies (preferably prospective in nature) to 
include TIA patients. Those could give researchers the opportunity to investigate 
whether stroke related factors itself would be related to behavioural deficits or that 
other, for example adaptive mechanisms to a life event could play a role.  
Future perspectives – “clinical prediction”
Prospective studies are needed to provide more insight into the time-course of 
the several behavioural consequences after stroke (described in this thesis) and 
to identify which factors are associated with the persistence or development of 
these consequences in the long-term. 
Stroke patients are at increased risk for developing post-stroke dementia [29] 
(which is even three times higher than the risk of a recurrent stroke [30]). To date, 
it is not possible to identify stroke patients that are at risk for post-stroke dementia. 
Our fMRI study may provide diagnostic opportunities for this identification. 
We found evidence that despite the absence of direct ischemic structural damage 
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of the MTL, an impaired function of the MTL plays a role in the development of 
memory dysfunction after stroke. Longitudinal studies are now needed to 
determine whether those with impaired MTL functionality are indeed at increased 
risk for post-stroke dementia. Furthermore, these fMRI studies may be combined 
with diffusion tensor imaging (DTI) in order to study the possible underlying 
structural correlate of the functional network. DTI is increasingly being used to 
investigate the structural integrity of white matter tracts and networks and can 
provide insight into the physiology and pathophysiology of organisation of 
cerebral networks during the development of several behavioural consequences 
after stroke. The execution of these so called multimodal MRI studies will be one 
of the research objectives for the near future of stroke related behavioural 
complaints. 
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Cerebrovasculair accident (CVA) is wereldwijd een belangrijke doodsoorzaak en 
heeft een grote invloed op de kwaliteit van leven. Na een intensieve medische 
behandeling treedt het meeste lichamelijke herstel kort na een CVA op. Deze 
“zichtbare” gevolgen (zoals hemiparese, afasie en visuele problematiek) die vaak 
kort na een CVA op de voorgrond treden, verdienen de meeste aandacht van 
zowel dokters als familieleden. Domweg doordat deze zo zichtbaar zijn. Dit 
proefschrift richt zich juist op de “niet-zichtbare” (of secundaire) gevolgen van 
een CVA, die vaak pas later duidelijk worden of pas duidelijk worden als er 
expliciet naar wordt gevraagd. Voorbeelden hiervan zijn depressieve symptomen, 
geheugenklachten en vermoeidheid. De studies beschreven in dit proefschrift 
proberen meer inzicht te krijgen in de epidemiologie en pathophysiologie van de 
hierboven genoemde secundaire gevolgen van een CVA. Daarvoor is in 2005 de 
Nijmeegse Stroke Studie opgericht. Deze prospectieve database verzamelt van 
alle CVA patiënten die opgenomen zijn geweest op de afdeling neurologie van het 
Radboud Universiteit Nijmegen, Medisch Centrum de demografische, klinische, 
radiologische en neuropsychologische gegevens. 
Er bestaat een doorlopend debat over de oorzaak van de bovengenoemde 
secundaire gevolgen van een CVA. Een aantal wetenschappers is van mening dat 
de locatie van een laesie belangrijk is, net zoals een verlamming na een 
herseninfarct in de pyramidebaan. Andere wetenschappers beweren dat de 
secundaire gevolgen na een CVA een psychologische reactie is op een “major life 
event” of als een reactie op lichamelijke afhankelijkheid. 
Hoofdstuk 2: Depressieve symptomen ná een CerebroVasculair Accident
Hoofdstuk 2.1 beschrijft van 107 studies de prevalentie van depressieve 
symptomen na een CVA, het beloop van deze symptomen gedurende de tijd en 
de risicofactoren voor depressieve symptomen na een CVA. In tegenstelling tot 
laesie locatie of grootte, werd in dit overzichtsartikel,  fysieke beperkingen na een 
CVA en depressiviteit in de medische geschiedenis wel gerelateerd aan 
depressieve symptomen na een CVA. Echter, al deze studies corrigeren nauwelijks 
voor factoren die reeds aanwezig zijn vóór de CVA, de zogenaamde confounders. 
Deze confounders (bijv depressieve symptomen in de medische geschiedenis, 
witte stof afwijkingen, stille infarcten, cerebrale atrofie) kunnen gerelateerd zijn 
aan depressieve symptomen ongeacht een CVA en kan daardoor de relatie 
tussen uitkomst en CVA mogelijk vertroebelen. 
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Hoofdstuk 2.2 onderzoekt bij 420 patienten de prevalentie en risicofactoren van 
depressieve symptomen, twee maanden ná een CVA. Mogelijke confounders 
zoals depressieve symptomen in de medische geschiedenis, witte stof afwijkingen 
en cerebrale atrophy, werden nadrukkelijk in acht genomen. De prevalentie van 
depressieve symptomen twee maanden na de CVA was 13%. De mate van 
handicap en functionele afhankelijkheid na de CVA waren risicofactoren voor 
depressieve symptomen na een CVA. Om meer inzicht te krijgen in de 
achterliggende oorzaak van depressieve symptomen ná een CVA werden ook TIA 
patiënten onderzocht. Deze patiënten maken een soort gelijke episode mee in 
vergelijking tot patiënten met een herseninfarct, maar bij TIA’s herstellen de 
“zichtbare” gevolgen na een CVA binnen 24 uur en radiologische afwijkingen in 
het brein zijn nauwelijks waar te nemen. Ondanks dat TIA patiënten geen blijvende 
“zichtbare” beperkingen laten zien, is de prevalentie van depressieve symptomen 
na een CVA vergelijkbaar met die van patiënten met een herseninfarct.    
Hoofdstuk 3: Cognitieve klachten ná een CerebroVasculair Accident
Hoofdstuk 3.1 beschrijft van 65 studies de prevalentie, risicofactoren en beloop 
van geheugenklachten na een CVA. De diagnose vasculaire dementie (waarbij 
de aanwezigheid van geheugenklachten/geheugenstoornissen een belangrijke 
voorwaarde is) wordt vaak binnen drie maanden na een CVA vastgesteld. Daarbij 
wordt gemakshalve er vanuit gegaan dat de geheugenklachten na een CVA een 
stabiel beloop hebben. Echter, onze gestructureerde literatuurstudie laat zien dat 
maar weinig studies (n=5) het beloop van geheugenklachten na een CVA over 
meerdere momenten hebben bestudeerd. Deze studies laten juist een hogere 
prevalentie zien van geheugenklachten kort na een CVA en een lagere prevalentie 
langere tijd na een CVA. Het is dus zeer goed mogelijk dat de diagnose vasculaire 
dementie (die per definitie binnen drie maanden na een CVA wordt vastgesteld) 
bij sommige patiënten niet meer van toepassing is naarmate de tijd na een CVA 
verstrijkt. Opnieuw diagnosticeren van vasculaire dementie na een CVA zou 
daarvoor wenselijk zijn. Risicofactoren voor geheugenklachten na een CVA zijn 
toename laesie volume, cerebrale atrofie en wittestof afwijkingen. Voor de 
interpretatie van deze uitkomsten moeten wel een aantal methodologische 
aandachtspunten in acht genomen worden. De 65 studies variëren sterk in: 1) 
patiënt inclusie (hoeveelheid, leeftijd, geslacht, eerste CVA of eerdere CVA’s), 2) 
verschillende meetinstrumenten voor geheugenklachten, 3) wisselende tijds - 
momenten van geheugentesten na een CVA en 4) verzamelen van karakteristieken 
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ná de CVA (laesie locatie, volume) en vóór de CVA (wittestof afwijkingen, cerebrale 
atrofie). Deze variatie maakt het lastig studies onderling te vergelijken en dus ook 
de etiologie van geheugenklachten vast te stellen. Het is daarom belangrijk om 
gegevens structureel en gestandaardiseerd te verzamelen.
Met behulp van functionele MRI wordt in hoofdstuk 3.2 onderzocht wat de 
achterliggende oorzaak van geheugenklachten is. Cognitieve klachten kunnen 
veelal verklaard worden door de grootte en locatie van een herseninfarct, maar 
voor geheugenklachten geldt dit niet. Geheugenklachten worden frequent 
genoemd na een CVA, echter een infarct in dat deel van het brein wat essentieel 
is voor het geheugen (de mediale temporaal kwab) komt zelden voor. In dit 
hoofdstuk onderzoeken we met behulp van fMRI de functionaliteit van de mediale 
temporaal kwab bij 22 gezonde controles en 28 patiënten met een herseninfarct. 
De functionaliteit van de mediale temporaal kwab hangt af van intacte verbindingen 
met andere hersengebieden verspreid over het gehele brein. Geheugenklachten 
na een herseninfarct zijn niet gerelateerd aan vermindering in structuur van de 
mediale temporaal kwab, maar in verminderding van functie van de mediale 
temporaal kwab. Verder onderzoek moet uitwijzen of patiënten met verminderde 
mediale temporaal kwab functionaliteit ook een verhoogd risico hebben op het 
ontwikkelen van vasculaire dementie.
Hoofdstuk 4: Vermoeidheid ná een CerebroVasculair Accident
Bij veel neurologische aandoeningen speelt vermoeidheid een belangrijke rol, 
zeker omdat het een negatieve impact heeft op het rehabilitatieproces. De meeste 
studies bestuderen vermoeidheid kort na een CVA of juist alleen langere tijd na 
een CVA. Daarbij wordt nauwelijks rekening gehouden met confounders die vóór 
de beroerte reeds aanwezig waren (bijv depressieve symptomen in de medische 
geschiedenis, wittestof afwijkingen, cerebrale atrofie) en gerelateerd zijn aan 
vermoeidheid ongeacht een CVA. Hoofdstuk 4.1 bestudeert de prevalentie van 
vermoeidheid na een CVA, het beloop van vermoeidheid gedurende de tijd en de 
risicofactoren voor vermoeidheid na een CVA. Meer dan 100 CVA patiënten 
werden twee maanden én 1.5 jaar na een CVA onderzocht. Mogelijke confounders 
(zoals depressieve symptomen in de medische geschiedenis, wittestof afwijkingen 
en cerebrale atrophy) werden nadrukkelijk in acht genomen. De prevalentie van 
vermoeidheid twee maanden én 1.5 jaar na de CVA was respectievelijk 35% en 
33%. Risicofactoren voor vermoeidheid twee maanden na een CVA zijn: lagere 
leeftijd, depressieve symptomen en infratentoriële infarcten. De risicofactor voor 
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vermoeidheid 1.5 jaar na een CVA is vermoeidheid twee maanden na een CVA. 
Voorspellers voor het ontwikkelen van vermoeidheid 1.5 jaar na een CVA zijn: 
depressieve symptomen en vermoeidheid twee maanden na een CVA. Vroegtijdige 
vermoeidheidsinterventies, die momenteel worden ontwikkeld, kunnen mogelijk 
helpen bij het voorkómen van vermoeidheid langere tijd na een CVA.     
Hoofdstuk 5: Samenvatting en discussie
In dit laatste hoofdstuk worden de belangrijkste bevindingen van het proefschrift 
beschreven. Verder worden methodologische aspecten aangedragen om niet 
alleen de verschillende studies beschreven in dit proefschrift kritisch te kunnen 
interpreteren, maar ook de hiaten van de bestaande literatuur. Als laatste wordt 
de klinische relevantie van de desbetreffende studies beschreven en worden 
suggesties aangedragen voor zowel methodologisch als klinisch wetenschappelijk 
onderzoek. 
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Allereerst gaat mijn dank uit naar alle patiënten en controle personen die mee 
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de zere plek te leggen en dat heeft dit onderzoek des te sterker gemaakt. Ik ben 
trots dat ik jouw eerste promovendus ben, mijn dank voor de samenwerking al die 
jaren! 
Karin Kanselaar, super leuk dat jij mijn paranimf wil zijn. Toen ik als junior 
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te volgen, wat je ook zeker gaat lukken…als je je maar aan de planningen houdt! 
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Natuurlijk wil ik mijn kamergenoten van de kleine onderzoekskamer mijn dank 
overbrengen; Lars (mijn vaste roomie, fijne vent, befaamd fietser en enige man op 
de kamer), Charlotte (expert in de ziekte van Parkinson en onze dokter), Loes 
(nieuwste aanwinst van de kamer), Nicol (altijd fanatiek in wat ze ook doet), Maja 
(oftewel Dr. Stulemeijer, perfectionisme op en top…zelfs op de blokfluit) en 
Teuntje (welliswaar geen stekkie op de kamer maar altijd bereid tot een gesprekje). 
Aangezien we allen zo verschillend zijn, waren onze gesprekken/discussies ook 
erg divers, maar interesse vóór elkaar en lol mét elkaar waren toch wel de dingen 
die ons een heus team maakte en mede daarom ook het promoveren leuk maakte. 
Heel veel succes de komende tijd voor ieder van jullie en ik zal het intensieve 
contact missen!
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Ook aan mijn ‘niet neurologie’ collega’s wil ik graag mijn dank overbrengen; 
Doctor Carlijn Hooijmans, al hebben we maar kort met elkaar gewerkt (1 week om 
precies te zijn!) hadden we gelijk een band die we sindsdien (>4 jaar) niet meer 
hebben losgelaten, jammer dat je momenteel op wereldreis bent!? Clemens 
Jansen, mijn FCDC maatje! Naast al die uren analyseren, wist jij mijn brein te 
voeden met muzikale/filosofische/psychologische bijzonderheden. Sieberen van 
der Werf, dank voor alle inspanningen wat tot twee artikelen in dit proefschrift 
heeft geleid. Mark Rijpkema, voor het wegwijs maken in de wereld van fMRI en 
voor de hulp bij “ongelukken” met SPM. Paul Gaalman, voor het leren omgaan 
met een 1.5 Tesla MRI-scanner waardoor ik zelfs certified user werd! Last but not 
least, Norbert Janssen voor het meedenken en het opzetten van de CVA database, 
maar ook voor de ontelbare keren dat ik weer patiënten wilde verwijderen, jumpjes, 
instructieschermpjes en vragenlijsten wilde toevoegen of veranderen!
Ik heb gemerkt dat wetenschap bedrijven het beste gaat als je zo nu en dan uit 
dat wereldje wordt getrokken en wie kunnen dat beter dan je beste vrienden…
Eelkje, Bram, Heleen, Martijn, Laura en Sjoert, door de jaren heen hebben we 
vele leuke dingen (en soms ook wel domme) gedaan, en zoals jullie weten ben ik 
blij met zulke echte vrienden, dat wil ik jullie even laten weten! Verder wil ik de 
baasjes, Klup Met, Karin Mentink, Nicole Verstappen, Eveline Kamping, Laura 
Koster, Anne Kan en Ellen Meuleman bedanken voor alle afleiding die ik het 
afgelopen jaar steeds meer nodig had…hopelijk gaan we op deze voet verder.
Lieve Leone, mijn grote zus, alhoewel onze interesses en ideeën vroeger heel ver 
van elkaar af lagen, komen ze nu wel héél dichtbij. Ik ben blij dat je als paranimf 
op dit belangrijke moment in mijn leven aan mijn zijde wilt staan. Stan (gesprekstof 
hebben we genoeg), Joep (heerlijk neefje dat je bent), Lobke (klein als je bent en 
al zó belangrijk), Ben (pesten lijkt je hobby), Ineke (vol interesse in eigenlijk alles), 
Daan (stoere zelfstandige kerel met een klein hartje) en Annemien (vanaf moment 
één, zat het goed) wat is het toch fijn om te weten dat je familie altijd achter je 
staat!
Lieve mamma en pappa, een warm nest, jezelf ontplooien, optimisme en genieten, 
zijn kenmerkend voor jullie. Met die ideeën in mijn binnenzak ben ik gekomen 
waar ik nu ben. Bedanken is in deze context zo formeel, ik wil jullie gewoon laten 
weten dat ik ontzettend veel van jullie hou en hoop dat ik nog heel wat gezellige 
en interessante gesprekken met jullie mag voeren! 
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Jeroen, mijn mannetje, jij bent de afgelopen tijd mijn stabiele factor geweest en 
het is heerlijk om te weten dat jij dat ook de komende tijd zult zijn. We koesteren 
bijzondere momenten in Europa, Azië, Afrika, Amerika en Australië… ik kan niet 
wachten tot ons volgend avontuur!!!   
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